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Abstract 
The N-end rule relates the regulation of the in vivo half-life of a protein to the identity of its 
N-terminal residue. Degradation signals (degrons) that are targeted by the N-end rule pathway 
include a set called N-degrons. The main determinant of an N-degron is a destabilizing N-terminal 
residue of a protein. In eukaryotes, the N-end rule pathway is a part of the ubiquitin system and 
consists of two branches, the Ac/N-end rule and the Arg/N-end rule pathways. The Ac/N-end rule 
pathway targets proteins containing Nα-terminally acetylated (Nt-acetylated) residues. The Arg/N-end 
rule pathway recognizes unacetylated N-terminal residues and involves N-terminal arginylation. 
Together, these branches target for degradation a majority of cellular proteins. For example, more 
than 80% of human proteins are cotranslationally Nt-acetylated. Thus most proteins harbor a specific 
degradation signal, termed AcN-degron, from the moment of their birth. Specific N-end rule pathways 
are also present in prokaryotes and in mitochondria. Enzymes that produce N-degrons include 
methionine-aminopeptidases, caspases, calpains, Nt-acetylases, Nt-amidases, arginyl-transferases and 
leucyl-transferases. Regulated degradation of specific proteins by the N-end rule pathway mediates a 
legion of physiological functions, including the sensing of heme, oxygen, and nitric oxide; selective 
elimination of misfolded proteins; the regulation of DNA repair, segregation and condensation; the 
signaling by G proteins; the regulation of peptide import, fat metabolism, viral and bacterial 
infections, apoptosis, meiosis, spermatogenesis, neurogenesis, and cardiovascular development; and 
the functioning of adult organs, including the pancreas and the brain. Discovered 25 years ago, this 
pathway continues to be a fount of biological insights. 
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1. Glossary of terms 
•  ‘Sequelog’ and ‘spalog’ denote, respectively, a sequence that is similar, to a specified 
extent, to another sequence, and a three-dimensional (3D) structure that is similar, to a specified 
extent, to another 3D structure1. Derivatives of these terms include ‘sequelogous’ and ‘sequelogy’ 
(sequence similarity); ‘spalogous’ and ‘spalogy’ (spatial similarity). In addition to their usefulness as 
separate terms for sequence and spatial similarities, the rigor-conferring advantage of ‘sequelog’ and 
‘spalog’ is their evolutionary neutrality, in contrast to interpretation-laden terms such as ‘homolog’, 
‘ortholog’ and ‘paralog’. The latter terms are compatible with the sequelog/spalog terminology and 
can be used to convey understanding about functions and common descent, if this (additional) 
information is available1. 
• Ubiquitin (Ub): a highly conserved 76-residue eukaryotic protein that can be enzymatically 
conjugated to other proteins, thereby marking them for processive degradation or other metabolic 
fates. 
• N-end rule: it relates the regulation of the in vivo half-life of a protein to the identity of its 
N-terminal residue. 
• N-end rule pathway: a proteolytic pathway whose physiological targets include proteins with 
destabilizing N-terminal residues. 
• Degron: a degradation signal2. 
• N-degron: one class of degradation signals that can be targeted by an N-end rule pathway. 
The main determinant of an N-degron is either a modified or unmodified destabilizing N-terminal 
residue of a protein. 
• Pro-N-degron: precursor of N-degron. A pro-N-degron is a specific sequence or 
conformational determinant of a polypeptide chain that can be cleaved or otherwise modified to 
produce a destabilizing N-terminal residue. This definition of a pro-N-degron implies that other 
determinants of an N-degron, e.g., a ‘targetable’ internal Lys residue of a substrate, are in place as 
well. 
• N-recognin: recognition component of an N-end rule pathway that recognizes (binds to) 
specific N-degrons. 
• Ndp residue: a primary (‘p’) destabilizing N-terminal residue, i.e., an unmodified N-terminal 
residue that is directly recognized by an N-recognin. 
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• Nds residue: a secondary (‘s’) destabilizing N-terminal residue, i.e., a residue whose 
destabilizing activity requires a specific preliminary modification, such as, for example, N-terminal 
arginylation (Nt-arginylation). 
•  Ndt residue: a tertiary (‘t’) destabilizing N-terminal residue, i.e., a residue whose 
destabilizing activity requires two preliminary modifications. 
• Arg/N-end rule pathway: a branch of the eukaryotic N-end rule pathway that involves the 
Nt-arginylation of protein substrates and also the targeting of unmodified bulky hydrophobic and 
basic N-terminal residues by an N-recognin E3 ubiquitin ligase. 
• Ac/N-end rule pathway: a branch of the eukaryotic N-end rule pathway that may also be 
present in archaeal prokaryotes. The Ac/N-end rule pathway involves the Nα-terminal acetylation 
(Nt-acetylation) of nascent proteins whose N-termini bear either Met or the small uncharged residues 
Ala, Val, Set, Thr or Cys. These residues become N-terminal after the cotranslational removal of Met 
by Met-aminopeptidases. Nt-acetylated proteins are targeted for degradation by the Ac/N-end rule 
pathway3. 
• Leu/N-end rule pathway: a bacterial N-end rule pathway that involves Nt-leucylation of 
protein substrates by specific L-transferases and also the targeting of bulky hydrophobic N-terminal 
residues by the ClpS N-recognin, an adaptor protein that delivers bacterial N-end rule substrates to 
the ClpAP protease. 
 
2. Introduction 
The lifespans of protein molecules in a cell range from less than a minute to many days. 
Among the functions of intracellular proteolysis are the elimination of misfolded or otherwise 
abnormal proteins, the maintenance of amino acid pools in cells affected by stresses such as 
starvation, and the generation of protein fragments that act as hormones, antigens, or other effectors. 
One major role of proteolytic pathways is the selective destruction of regulatory proteins whose 
concentrations must vary with time and alterations in the state of a cell. A short in vivo half-life of a 
protein provides a way to generate its spatial gradient and to rapidly adjust its concentration or 
subunit composition through changes in the rate of its degradation. Proteolysis can also act to activate 
protein molecules and specific circuits, by removing an autoinhibitory protein domain or by 
selectively destroying an inhibitory subunit of a protein complex. The regulated (and processive) 
degradation of intracellular proteins is carried out largely by the ubiquitin-proteasome system (Ub 
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system) (Fig. 1A), in conjunction with molecular chaperones, autophagy and lysosomal proteolysis. 
Chaperones mediate in vivo protein folding and the assembly/disassembly of protein complexes. A 
meta-system that includes the Ub system and chaperones determines the time-dependent probability, 
for each protein, of being either in its ‘normal’ (functional) state, or targeted for degradation, or 
perturbed in ways (including aggregation) that may or may not lead to degradation. Other 
contributors to intracellular proteolysis include cytosolic and nuclear proteases such as caspases and 
calpains. These and other nonprocessive proteases can function as ‘upstream’ components of the Ub 
system, producing protein fragments that are often targeted and degraded to short peptides by 
Ub-mediated pathways. Proteins that are damaged, misfolded or otherwise abnormal are usually 
short-lived in vivo, with significant exceptions that include a subset of perturbed proteins (and/or their 
aggregates) that are harmful but cannot be efficaciously repaired or removed. The resulting 
proteotoxicity underlies both aging and specific diseases, including neurodegeneration. 
The N-end rule relates the regulation of the in vivo half-life of a protein to the identity of its 
N-terminal residue. The 1986 discovery of the N-end rule pathway identified the first specific 
pathway of the Ub system4-6. It was also the discovery of the first primary degradation signals 
(degrons2) in short-lived proteins4. Ub, a 76-residue protein, is a ‘secondary’ degron in that Ub is 
conjugated to proteins that contain primary degradation signals. For accounts of the early history of 
the Ub field, see refs. 6-8. Over the last quarter century, the understanding of the N-end rule pathway 
has advanced to such an extent that a comprehensive review of the pathway has to be an uncommonly 
large paper. 
 
3. Overview of the N-end rule pathway 
N-terminal degradation signals of the N-end rule pathway are called N-degrons. The main 
determinant of an N-degron is a destabilizing N-terminal residue of a protein3-6,9-44 (Figs. 2-5). In 
eukaryotes, the N-end rule pathway is a part of the Ub system, which mediates selective protein 
turnover through the conjugation of Ub to specific proteins, thereby marking them for degradation by 
the 26S proteasome, a multisubunit ATP-dependent protease6,45-65 (Fig. 1A). Prokaryotes, i.e., 
bacteria and archaea, contain Ub-like proteolytic pathways but lack the bona fide Ub system66-70. 
Nevertheless, prokaryotes contain specific versions of the N-end rule pathway that do not involve 
ubiquitylation5,6,14-16,37,71-78 (Fig. 5). 
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Recognition components of the N-end rule pathway are called N-recognins5. In bacteria, the 
12-kDa ClpS, identified as an N-recognin by the Bukau laboratory72, binds to N-degrons of N-end 
rule substrates and delivers them to the ATP-dependent ClpAP protease16,72,74,76-82 (Fig. 5 and 
Fig. 6B-D). In eukaryotes, N-recognins are E3 Ub ligases that bind to specific 
N-degrons3,5,6,22,30,38,39,43,83-85 (Fig. 7 and Fig. 8). A complex of an E3 N-recognin and its cognate E2 
Ub-conjugating enzyme polyubiquitylates N-end rule substrates at their internal Lys residues, thereby 
targeting these proteins for degradation by the 26S proteasome9,11 (Fig. 2 and Fig. 3). The term 
‘Ub ligase’ denotes either an E2-E3 complex or its E3 component6,54,57,62. In eukaryotes, the N-end 
rule pathway comprises two major branches, one of which is termed the Arg/N-end rule pathway. 
This branch involves the N-terminal arginylation (Nt-arginylation) of protein substrates and also the 
targeting of specific unmodified N-terminal residues by E3 N-recognins (Fig. 2A and Fig. 3). The 
other branch is termed the Ac/N-end rule pathway3. It involves the cotranslational Nα-terminal 
acetylation (Nt-acetylation) of nascent proteins86-95 whose N-termini bear either Met or the small 
uncharged residues Ala, Val, Ser, Thr or Cys. These residues become N-terminal after the 
cotranslational removal of N-terminal Met by Met-aminopeptidases96-101 (Fig. 1C, D). Nt-acetylated 
proteins are targeted for regulated degradation by the Ac/N-end rule pathway3 (Fig. 2B). 
The Nt-acetylated Met, Ala, Val, Ser, Thr and Cys residues of newly formed proteins 
comprise a specific class of N-degrons, termed AcN-degrons3 (Fig. 2B and Fig. 4A). The 
cotranslational Nt-acetylation of nascent proteins87-95,102 (Fig. 1C) is both enzymatically and 
functionally distinct from the largely posttranslational acetylation of internal residues in many 
proteins103,104. Nt-acetylation and internal acetylation are carried out by (mostly) nonoverlapping sets 
of specific acetylases. In addition, Nt-acetylation is apparently irreversible. No Nt-deacetylases have 
been identified, in contrast to a dynamic internal acetylation/deacetylation, with specific deacetylases 
removing internally conjugated acetyl groups (ref. 104 and refs. therein). As described below, the 
proteolytic function of Nt-acetylation (Fig 2B) is likely to be relevant to more than 80% of the entire 
proteome, i.e., to thousands of Nt-acetylated proteins3. In contrast, either an identified or inferred 
necessity of Nt-acetylation for other (nonproteolytic) functions involves, at present, only 
~10 Nt-acetylated proteins (refs. 92,105-110 and refs. therein). 
Apart from expanding the N-end rule and its functions, the 2010 discovery of the Ac/N-end 
rule pathway3 has also revealed the main physiological roles of two classes of enzymes, Nt-acetylases 
and Met-aminopeptidases. Specifically, Nt-acetylases produce AcN-degrons while the ‘upstream’ 
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Met-aminopeptidases, by cleaving off the N-terminal Met residue, make these degradation signals 
possible, all of them save for those AcN-degrons that contain the Nt-acetylated N-terminal Met 
(Fig. 1C, D and Fig. 2B). Nt-acetylases and Met-aminopeptidases are essential and universally 
present enzymes86-101 whose physiological functions had been largely unknown. These enzymes are 
now specific components of the Ac/N-end rule pathway3 (Fig. 2B). 
N-terminal Arg, Lys, His, Leu, Phe, Tyr, Trp, Ile, Asp, Glu, Asn, Gln, and Cys comprise the 
main determinants of N-degrons in the Arg/N-end rule pathway (Fig. 2A and Fig. 3). Among these 
N-degrons, the unmodified basic (Arg, Lys, His) and bulky hydrophobic (Leu, Phe, Tyr, Trp, Ile) 
N-terminal residues are recognized directly by cognate E3 N-recognins (Fig. 2A, Fig. 3, Fig. 7 and 
Fig. 8). These E3s contain highly spalogous (spatially similar1) ~80-residue regions called UBR 
domains or type-1 binding sites83-85. Folded around three zinc ions, a UBR domain binds to 
N-terminal Arg, Lys or His, the type-1 primary destabilizing residues of N-end rule substrates (Fig. 3 
and Fig. 8). Another (usually adjacent) region of UBR-type N-recognins, called the type-2 binding 
site, recognizes N-terminal Leu, Phe, Tyr, Trp or Ile, which are called the type-2 primary 
destabilizing residues (Fig. 7A). Together, the directly recognized primary destabilizing N-terminal 
Arg, Lys, His, Leu, Phe, Tyr, Trp and Ile are denoted as Ndp residues (N, N-terminal; d, destabilizing; 
p, primary)6,43,83-85. In contrast to these residues, the N-terminal Asp, Glu, Asn, Gln and Cys function 
as destabilizing residues through their preliminary modifications. One of these modifications is 
Nt-arginylation. N-terminal Arg is an Ndp residue, i.e., it can be recognized by E3 N-recognins of the 
Arg/N-end rule pathway (Fig. 2A and Fig. 3). Arg-tRNA-protein transferase (R-transferase) 
conjugates Arg to N-terminal Asp, Glu or oxidized Cys of proteins or short peptides, with Arg-tRNA 
as the cosubstrate and the donor of Arg. R-transferases are encoded by Ate1 and its sequelogs from 
yeast to mammals but are absent from examined prokaryotes32,35,36,111-114 (Fig. 9). In contrast to 
N-terminal Asp, Glu and oxidized Cys, the N-terminal Asn and Gln residues cannot be arginylated by 
R-transferase. However, the Arg/N-end rule pathway contains specific N-terminal amidases 
(Nt-amidases) that convert N-terminal Asn and Gln to Asp and Glu, respectively, followed by their 
Nt-arginylation23,25,42,115-117 (Fig. 2A and Fig. 3). 
N-terminal Cys residues can be Nt-acetylated (in proteins that contain the initially present 
N-terminal Met-Cys sequence) after the cotranslational removal of N-terminal Met by 
Met-aminopeptidases (Fig. 1C, D). The same is true for other second-position (penultimate) small 
residues such as Ala, Val, Ser or Thr. Nt-acetylation of Cys produces an AcN-degron of the Ac/N-end 
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rule pathway and thereby precludes the (alternative) participation of N-terminal Cys in the Arg/N-end 
rule pathway3 (Fig. 2B; cf. Fig. 3). However, some sequence contexts, e.g., a basic residue at 
position 2, inhibit the Nt-acetylation of N-terminal Cys and other N-terminal residues. The 
mammalian proteins Rgs4, Rgs5 and Rgs16 are one example of this inhibition. They bind to Gα 
subunits of specific G proteins and increase the intrinsic GTPase activity of Gα, thereby 
down-regulating the signaling by these G proteins. The N-terminal Cys residue of Rgs4, Rgs5 and 
Rgs16 is followed by a basic residue (Fig. 10), hence the absence of Nt-acetylation of these RGS 
proteins32,33,118. (Whereas in the yeast Saccharomyces cerevisiae a basic residue at position 2 suffices 
to block Nt-acetylation, some proteins with position-2 basic residues can be Nt-acetylated in 
mammalian cells91.)  
In addition, conditional cleavages of cellular proteins by nonprocessive proteases such as 
caspases or calpains can also produce C-terminal fragments that bear unmodified N-terminal Cys 
residues. If the protein’s N-terminal Cys can be oxidized through (apparently nonenzymatic) 
reactions that require both nitric oxide (NO) and oxygen, and if these compounds are present in a cell 
at sufficient levels, the resulting N-terminal Cys-sulfinate or Cys-sulfonate (but not the original Cys) 
can be Nt-arginylated by the Ate1 R-transferase32,33. The necessity of NO and oxygen for the 
destabilizing activity of N-terminal Cys makes the Arg/N-end rule pathway a sensor of both NO and 
oxygen (Section 9.4). In sum, depending on specific protein substrates and in vivo conditions such as 
the presence of NO, the N-terminal Cys of a protein can function either as an NO/O2-mediated N-
degron of the Arg/N-end rule pathway or, alternatively, as an AcN-degron of the Ac/N-end rule 
pathway3,32,33 (Fig. 2B and Fig. 3). 
N-terminal Asp, Glu, Asn, Gln and Cys that are targeted by the Arg/N-end rule pathway are 
termed ‘secondary’ (Nds) or ‘tertiary’ (Ndt) destabilizing residues, depending on the number of 
specific modifications (arginylation of Asp and Glu; deamidation/arginylation of Asn and Gln; 
oxidation/arginylation of Cys) that precede the targeting and polyubiquitylation, by N-recognins, of 
Nt-arginylated Arg/N-end rule substrates15,32,33,36,41,42. Analogously, the N-terminal Met, Ala, Val, 
Ser, Thr and Cys residues that become AcN-degrons after the Nt-acetylation of these residues, are 
classed as Nds (secondary destabilizing N-terminal) residues, because they must be Nt-acetylated 
before their targeting by N-recognins of the Ac/N-end rule pathway3 (Fig. 2B). 
Together, the Arg/N-end rule and Ac/N-end rule pathways target a majority of cellular 
proteins for regulated degradation. For example, more than 80% of human proteins are 
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cotranslationally Nt-acetylated by a family of ribosome-associated Nt-acetylases that act after 
Met-aminopeptidases, which are also bound to the ribosomes89,91,92,95 (Fig. 2B). Thus, remarkably, 
most proteins harbor a specific degradation signal (AcN-degron) from the moment of their birth3. 
Posttranslational Nt-acetylation of proteins can occur as well (J.-H. Oh and A.V., unpubl. data), 
presumably because there is a significant pool of Nt-acetylases that are not bound to ribosomes. 
In sum, N-degrons of the Ac/N-end rule and Arg/N-end rule pathways can be produced either 
cotranslationally or posttranslationally (and conditionally), by enzymes that include caspases, 
calpains, separases, other nonprocessive proteases, Nt-acetylases, Nt-amidases, and R-transferases. 
These enzymes function as upstream components of the N-end rule pathway, preparing its substrates 
for targeting and polyubiquitylation by N-recognins6,15,16 (Fig. 2 and Fig. 3). In contrast to 
Nt-arginylation in eukaryotes, N-end rule substrates that bear Nds residues in bacteria are 
Nt-leucylated by the Aat L/F-transferase or the Bpt L-transferase, which conjugate (largely) Leu, an 
Ndp residue, to N-terminal Nds residues of bacterial proteins, prior to their recognition by the ClpS 
N-recognin16,37 (Fig. 5). 
Physiological functions of the N-end rule pathway are strikingly broad and continue to be 
discovered. Regulated degradation of proteins by the eukaryotic Arg/N-end rule pathway (Figs. 2A 
and 3) mediates the sensing of heme, NO, oxygen and short peptides; the selective elimination of 
misfolded proteins; the regulation of DNA repair (through degradation of Mgt1, a DNA repair 
protein); the cohesion/segregation of chromosomes (through degradation of a subunit of cohesin); the 
signaling by transmembrane receptors (through degradation of the G-protein regulators Rgs4, Rgs5 
and Rgs16); the control of peptide import (through degradation of Cup9, the import’s transcriptional 
repressor); the regulation of apoptosis, meiosis, viral and bacterial infections, fat metabolism, cell 
migration, actin filaments, cardiovascular development, spermatogenesis, neurogenesis, and memory; 
the functioning of adult organs, including the brain, muscle, testis and pancreas; and the regulation of 
leaf and shoot development, leaf senescence and seed germination in plants 
(refs. 3,6,15,16,18,26,32,34,36,39-42,113,119-136 and refs. therein). Mutations in UBR1, an E3 
N-recognin of the human Arg/N-end rule pathway, cause Johanson-Blizzard syndrome (JBS). It 
comprises physical malformations, insufficiency and inflammation of the exocrine pancreas, and 
frequent mental retardation as well as deafness34. Remarkably, an N-recognin such as mammalian 
UBR2 can also function to protect specific proteins from degradation137. The recently discovered 
Ac/N-end rule pathway (Fig. 2B) is likely to mediate, among other things, protein quality control, the 
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regulation of in vivo stoichiometry of proteins that form multisubunit complexes, and the degradation 
of long-lived proteins3. Physiological roles of the bacterial (E. coli) N-end rule pathway include the 
regulated degradation of the Dps nucleoid-condensing protein and the YgjG putrescine 
aminotransferase76,77. 
 
4. Terminology and definitions 
The terms used in this review are defined above and in Glossary (Section 1). The notations 
‘Arg/N-end rule pathway’ and ‘Ac/N-end rule pathway’ (Fig. 2 and Fig. 3) should be applicable to 
any eukaryote, as they bring up a key modification, either Nt-arginylation (‘Arg’) or Nt-acetylation 
(‘Ac’) but do not invoke specific genes or proteins. In this terminology, the bacterial N-end rule 
pathway is called the Leu/N-end rule pathway, given its similarity (despite the absence of 
ubiquitylation) to the eukaryotic Arg/N-end rule pathway, with Nt-leucylation in bacteria versus 
Nt-arginylation in eukaryotes (Fig. 5). 
As an experimentally observed but formal (non-mechanistic) relation between the regulation 
of the in vivo half-life of a protein and the identity of its N-terminal residue, the N-end rule does not 
place constraints on the nature of processing steps (e.g., proteolytic cleavages) or specific enzymes 
that produce N-degrons and implement the N-end rule pathway5,6,15,16. An N-degron is classed as 
such if an unmodified or covalently modified N-terminal residue of a protein is an essential 
determinant of that protein’s degradation signal. (A protein may contain, and often does, other 
degrons as well.) This function-based definition does not specify molecular devices that produce, 
recognize or regulate N-degrons. It is also compatible with any route through which a destabilizing 
residue becomes N-terminal in a polypeptide. In sum, a feature that suffices to demarcate a 
processive proteolytic pathway as a branch of the N-end rule pathway is its ability to target specific 
N-terminal residues, unmodified or covalently modified. 
Substrate-binding sites of an E3 N-recognin that targets N-degrons of protein substrates are 
apparently always accessible, whereas other sites of the same E3, the ones that target internal degrons 
of other protein substrates, can be autoinhibited. This autoinhibition can be allosterically reversed by 
ligands such as short peptides that bind to the sites of N-recognin that target N-degrons27,29,38,138. 
Given these functionally important connections among different degron-recognizing sites of 
N-recognins, an intracellular protein is classed as a substrate of the N-end rule pathway if it is 
targeted by an N-recognin, irrespective of whether the targeting involves an internal degron of the 
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protein or an N-degron6. This hardware-centric (N-recognin-based) definition of substrates of the 
N-end rule pathway bypasses the semantically intractable issue of multiple binding sites in 
N-recognins. 
 
5. Substrates of the N-end rule pathway 
An N-degron can be produced from a pro-N-degron (precursor of N-degron) through a 
cotranslational or posttranslational proteolytic cleavage. Ribosome-associated Met-aminopeptidases 
cleave off the Met residue from the N-terminus of a nascent protein if the residue at position 2, to 
become N-terminal after cleavage, has a small enough side chain100,101 (Fig. 1D). Consequently, of 
the 13 residues that are destabilizing in the mammalian Arg/N-end rule pathway, only Cys can be 
made N-terminal by Met-aminopeptidases (Fig. 1D and Fig. 3). (Any destabilizing residue, including 
Cys, can be made N-terminal through posttranslational cleavages of proteins by other nonprocessive 
proteases6,28.) In contrast to larger residues at position 2, the second-position Ala, Val, Ser, Thr or 
Cys can be made N-terminal by Met-aminopeptidases3 (Fig. 1D). These residues, which are usually 
Nt-acetylated, are the secondary destabilizing (Nds) residues of the Ac/N-end rule pathway3 
(Fig. 2B). The initial N-terminal Met of a nascent protein is also an Nds residue of the Ac/N-end rule 
pathway, the only such residue that does not require a preliminary proteolytic cleavage to form an 
AcN-degron. If N-terminal Met is followed by a bulky residue, this Met is not cleaved off, and is 
usually Nt-acetylated3 (Fig. 1C, D and Fig. 2B). 
More than 80% of mammalian proteins are cotranslationally Nt-acetylated91-93. About 
20 Nt-acetylated proteins, largely in S. cerevisiae but also in mammalian cells and chosen nearly at 
random, have been examined, thus far, for the presence AcN-degrons, using methods that included 
pulse-chase and cycloheximide-chase assays, as well as genetic techniques. Nearly every one of the 
tested Nt-acetylated proteins was found to contain an AcN-degron (ref. 3; A. Shemorry, C.-S. Hwang, 
B. Wadas and A.V., unpubl. data). Given these results and the pervasiveness of Nt-acetylation, our 
current premise is that most cellular proteins can become substrates of the Ac/N-end rule pathway, 
either during their synthesis, or immediately afterwards, or significantly later (Fig. 2B). In contrast, 
the Arg/N-end rule pathway appears to target fewer substrates (but still hundreds of them; see below), 
in part because most N-degrons of this pathway are produced posttranslationally, through cleavages 
by proteases other than Met-aminopeptidases. That is so because second-position residues that are 
destabilizing in the Arg/N-end rule pathway are too large to be made N-terminal by 
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Met-aminopeptidases (Fig. 1D, Fig. 2A and Fig. 3). The sole exception is Cys (Fig. 4A). Specifically, 
the N-degrons of the mammalian Rgs4, Rgs5 and Rgs16 proteins (Sections 3 and 9.4) would be 
expected to form cotranslationally or nearly so in the presence of NO and other conditions that are 
conducive to oxidation of N-terminal Cys (Fig. 3 and Fig. 10). N-degrons also form cotranslationally 
in engineered N-end rule substrates that are expressed in vivo as Ub-X-protein fusions (in which X is 
a destabilizing residue), because deubiquitylases cotranslationally remove the fusion’s Ub 
moiety9,24,139. In addition, UBR-type E3 N-recognins of the Arg/N-end rule pathway recognize not 
only N-degrons but also internal (non-N-terminal) degradation signals (Fig. 2A and Fig. 3). Proteins 
that lack N-degrons but contain these internal degrons comprise yet another set of substrates of the 
Arg/N-end rule pathway. Only a few (out of probably many) such substrates have been identified so 
far (Section 9.4). 
Physiological substrates of the eukaryotic Arg/N-end rule pathway include the Drosophila 
melanogaster DIAP1 regulator of apoptosis140,141; the mammalian Rgs4, Rgs5, and Rgs16 regulators 
of G proteins32,33,118; the C-terminal fragments of the Scc1/Rad21 cohesin subunit that are produced 
by separase in eukaryotes from yeast to mammals (ref. 28; J. Zhou, D. Pati and A.V., unpubl. data); 
the human immunodeficiency virus-1 (HIV-1) integrase132,133; and the Listeria monocytogenes 
listeriolysin (Lys-LLO), which is secreted by this bacterium into the cytosol of infected mammalian 
cells124 (Fig. 10 and Section 9.4). In addition, the S. cerevisiae Mgt1 DNA repair protein and the 
Cup9 transcriptional repressor are targeted by the Arg/N-end rule pathway through their internal 
degrons (Section 9.4). Figure 10 and a brief description below cite the currently known substrates of 
the Arg/N-end rule pathway (other than Mgt1 and Cup9) and a few putative (unverified) N-end rule 
substrates that are a part of a much larger set of such substrates (A.V., unpubl. data). For some of 
these protein fragments, published evidence suggests their metabolic instability; other fragments have 
not been examined in this regard. 
1) C-terminal fragment of HEF1 (a focal adhesion-associated docking protein) that bears 
N-terminal Tyr (an Ndp residue) and is produced by caspases not only during apoptosis but during 
normal mitosis as well142,143 (Fig. 10). 
2) C-terminal fragment of the MET tyrosine kinase, a transmembrane receptor of HGF/SF, a 
hepatocyte growth factor-scatter factor. This fragment of MET is produced by caspases (if MET is 
not bound to HGF/SF) and bears N-terminal Tyr, an Ndp residue144-147. MET is a member of the 
family of more than 10 mammalian ‘dependence’ receptors (DRs). These transmembrane receptors 
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are usually not related by sequence or structure but are functionally analogous because of their ability 
to mediate two opposite physiological outcomes. In the presence of its cognate ligand, a DR receptor 
activates signaling pathways that mediate cell survival, migration and differentiation. However, in the 
absence of a cognate ligand, a DR receptor acquires an ‘opposite’ activity, i.e., it produces an 
apoptotic signal, often through the formation, by caspases or other nonprocessive proteases, of a 
proapoptotic C-terminal cytosolic fragment(s) that functions in the cytosol and/or the nucleus146,147. 
3) C-terminal fragment of the MYC oncoprotein, termed MYC-nick148, that is produced by 
calpain(s), bears N-terminal Arg (an Ndp residue), and exhibits physiological activities that are 
different from those of full-length MYC. 
4) C-terminal fragment of the ETK/BMX tyrosine protein kinase that is produced by caspases, 
bears N-terminal Trp (an Ndp residue), and is proapoptotic149. 
5) C-terminal fragment of the transmembrane EPHA4 ‘dependence’ receptor (item 2 
above146,147) that is produced by caspases (if EPHA4 is not bound to its ligand EPHB3) and bears 
N-terminal Asp, an Nds residue150. 
6) C-terminal fragment of the mouse Cdc42 GTP-binding protein that is produced by caspases 
and bears N-terminal Asp, an Nds residue151. 
7) C-terminal fragment of the MDM2 E3 Ub ligase (whose targets include p53) that is 
produced by caspases and bears N-terminal Cys, an Ndt residue152. 
8) C-terminal fragment of the protein kinase Cδ (PKCδ) that is produced by caspases, bears 
N-terminal Asn (an Ndt residue), and is proapoptotic, in contrast to the full-length PKCδ kinase153,154. 
9) C-terminal fragment of the protein kinase Cθ (PKCθ) that is produced by caspases, bears 
N-terminal Lys (an Ndp residue), and is proapoptotic, in contrast to the full-length PKCθ kinase153,155 
(Fig. 10). 
Many more substrates of the Arg/N-end rule pathway that contain N-degrons are likely to 
exist in mammals, but they remain either putative or unknown, given the logistics and uncertainties of 
current proteome-scale assays, and also because of insufficient knowledge about nonprocessive (and 
conditional) cleavages of intracellular proteins that yield in vivo N-end rule substrates. The expected 
multitude of such substrates stems from the existence of nonprocessive proteases that function, in 
particular, in the nucleus and/or cytosol and are known or expected to produce C-terminal fragments 
of specific proteins that bear destabilizing N-terminal residues of the Arg/N-end rule pathway. These 
proteases include Met-aminopeptidases96-101, caspases156-160, calpains, separase161,162, taspase163, 
Page 13 of 98
John Wiley & Sons
Protein Science
14 
 
MALT1 protease164, γ-secretase165, proteinase-3 (PR3)166, and viral proteases131-133. It should be 
emphasized that caspases cleave specific intracellular proteins not only in settings that lead to 
apoptotic cell death but also in pathways of cell differentiation that do not result in cell death158,159. In 
addition, if the cleavage of a protein by a caspase produces a proapoptotic C-terminal fragment, it 
being a short-lived N-end rule substrate would counteract apoptosis and thus ‘buffer’ a cell against 
toxicity of caspases that become active owing to a significant level of noise in caspase-activation 
circuits (Section 9.4). 
In addition to the substrates cited in Fig. 10, several other likely in vivo substrates of the Ate1 
R-transferase (Fig. 2A and Fig. 3) include protein disulfide isomerase (PDI), glucose-regulated 
protein 78 (Grp78), β-actin, γ-actin, and calreticulin35,127,128,130,135,136. Although the Ate1 R-transferase 
and the rest of the Arg/N-end rule pathway are apparently confined to the cytosol and the nucleus, 
and although calreticulin, Grp78 and PDI are present largely in the lumen of the endoplasmic 
reticulum (ER), a variety of evidence suggests that these proteins (lacking their cleaved-off signal 
sequences and bearing N-terminal Nds residues) are also present in the cytosol and other non-ER 
compartments, where they may become R-transferase substrates35,136. Partial Nt-arginylation of 
apparently long-lived proteins such as β-actin and calreticulin128,135,136 suggests that Nt-arginylation 
may have nonproteolytic functions as well. 
Hamilton et al. 167 characterized Go/Gi heterotrimeric G proteins purified from bovine brains. 
The bulk of the Gγ2 subunit of the Go protein had the expected N-terminal sequence 
Ac-ASNNTASIA, produced through the removal of N-terminal Met by Met-aminopeptidases and the 
(presumably) cotranslational Nt-acetylation of N-terminal Ala (Sections 3 and 8, and Fig. 2B). 
However, a minor but significant fraction of the Gγ2 subunit of Go protein had the N-terminal 
sequence RDTASIA. Such a sequence would be produced from ASNNTASIA via the removal 
(through a single cleavage or sequential proteolysis) of the first 3 residues (after initial Met) by an 
unknown protease, deamidation of the resulting N-terminal Asn by the Ntan1 NtN-amidase (Fig. 3 
and Section 9.2) and Nt-arginylation of the resulting N-terminal Asp by the Ate1 R-transferase167. 
The Arg-Gγ2 protein produced from engineered Ub-Arg-Gγ2 using the Ub fusion technique (Fig. 1B) 
was a short-lived N-end rule substrate in reticulocyte extract167. It remains to be determined whether 
Arg-Gγ2 is a physiological N-end rule substrate, because the still unexcluded possibility is that 
Arg-Gγ2 might be produced through in vitro proteolysis, Nt-deamidation and Nt-arginylation in 
crude extracts during purification of G proteins167.  
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The currently known physiological substrates of the bacterial Leu/N-end rule pathway (Fig. 5) 
are discussed in Section 10. 
 
6. Structure and targeting of N-degrons 
Mechanistic aspects of the N-end rule pathway that are critical for its functions include the 
regulation of E3 N-recognins, for example through a specific phosphorylation cascade39 (Fig. 7), and 
also through changes in the activity/accessibility of degrons in N-end rule substrates27,29,138. A key 
mechanistic capability of the N-end rule pathway is its subunit selectivity13,168, i.e., the ability to 
selectively target and destroy a subunit of a protein complex while sparing the rest of it (Fig. 11A-D). 
Examples of subunit-selective protein remodeling by the Arg/N-end rule pathway are described in 
Section 9.4. Although degrons that are targeted by the Ub system are many and varied, their design is 
fundamentally similar to the multi-determinant organization of N-degrons, the first primary 
degradation signals in short-lived proteins to be discovered and analyzed4,5,9,17,19,24 (Fig. 11A). 
The activity of N-degrons and other Ub-mediated degradation signals is a function of several 
variables5,9,17,19,168-171. One of them is the efficacy of a degron’s first determinant, i.e., a region of a 
protein substrate that is recognized by a cognate E3 Ub ligase. In the case of an N-degron that is 
targeted by the Arg/N-end rule pathway, this would be either an original or ‘acquired’ primary 
destabilizing (Ndp) residue (Fig. 2A and Fig. 3). Residues downstream from a substrate’s N-terminal 
Ndp residue, and particularly a residue at position 2, can modulate the binding of an E3 N-recognin to 
an N-end rule substrate38,83,84. If an initially formed N-degron (produced from a pre-N-degron) 
contains a secondary (Nds) or a tertiary (Ndt) destabilizing residue, the efficacy of N-degron’s first 
determinant would be determined, in addition, by the rate(s) of covalent modification(s) of the initial 
N-terminal residue that eventually yields an Ndp residue that can be bound by a cognate N-recognin. 
Thus the levels and activity of Nt-amidases and/or R-transferase (Fig. 2A and Fig. 3) would be 
expected to regulate the corresponding Nds/Ndt-based N-degrons. Yet another parameter that 
influences these preliminary stages of N-degron’s targeting is the extent of steric exposure of an Ndp 
residue and the extent of flexibility of a protein’s N-terminal region that would be expected to 
facilitate the binding of an Ndp residue by an N-recognin5,9. 
Once the N-terminal Ndp residue of a substrate is bound by a complex of N-recognin E3 and 
its associated Ub-conjugating (E2) enzyme, a race against time begins, given the transiency of the 
bound state and the necessity to produce a substrate-linked poly-Ub chain that is required for 
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downstream targeting steps. The synthesis of a poly-Ub chain (usually but not always a Lys48-type 
chain) is initiated, in most cases, at an internal Lys residue of the substrate9,11,168. In eukaryotes, this 
internal lysine is the second determinant of an N-degron (Fig. 11A). In some N-end rule substrates, 
only one internal lysine may be appropriately positioned for a kinetically efficacious attack on the 
thioester bond (denoted as ~) between E2 and Ub in the substrate-associated E3/E2~Ub complex. In 
other cases, including engineered N-end rule substrates9,20,24,168, more than one Lys residue of a 
substrate is capable of such an attack. Its successful completion usually preempts participation by 
alternative lysines and is followed by a processive synthesis of a substrate-linked poly-Ub by a 
substrate-bound N-recognin E2/E3 Ub ligase. For example, there are two efficaciously 
‘ubiquitylatable’ Lys residues, at positions 15 and 17, in an unstructured ~40-residue N-terminal 
extension of the 21-kDa mouse dihydrofolate reductase (DHFR), an engineered N-end rule substrate9. 
Either one of those lysines could be polyubiquitylated during the targeting, i.e., just one of two 
lysines (either one) had to be present for the activity of N-degron9. The otherwise identical but 
lysine-lacking N-terminal extension (with both lysines converted to Arg) did not result in the 
reporter’s degradation by the Arg/N-end rule pathway, despite the presence of a destabilizing 
N-terminal residue9 (Fig. 11A). 
In sum, the efficacy of a second-determinant Lys residue of a substrate’s N-degron is 
determined by the lysine’s spatial proximity to E2~Ub thioester of the targeting complex, and also by 
the extent of flexibility of a region containing the requisite lysine or lysines. This understanding of 
the necessity of an unstructured region (a requirement that is relevant to other Ub-dependent degrons 
as well) was produced by Bachmair and myself9 in 1989, in conjunction with the discovery, by Chau 
and colleagues in our laboratory, of the Lys48-type poly-Ub chains and their necessity for protein 
degradation11. We suggested that the main function of a substrate-linked poly-Ub chain is its physical 
binding to a specific site of the proteasome. By decreasing the rate of substrate dissociation, the 
resulting retention, through a poly-Ub chain, of a targeted substrate at the 26S proteasome would 
increase the probability of substrate unfolding and degradation by other components of the 
proteasome9,11. In 1989, specific ‘downstream’ degradation steps and their mediator, the 
26S proteasome, were just beginning to be defined experimentally, by several laboratories. With the 
above understanding of targeting in place by that time, it remained to be determined whether the 
demonstrated requirement for an unstructured region in N-end rule substrates9 was important only in 
the context of that region’s polyubiquitylation. In an alternative mechanism, the same region, or a 
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similar (unstructured) but separate region of a substrate would also be required for a 
proteasome-mediated step that would initiate the processive degradation of a substrate that had been 
captured through its poly-Ub chain. 
As predicted in 1989 (refs. 9,11), the 19S regulatory particle (RP) of the 26S proteasome was 
eventually shown to contain specific subunits that bind to a poly-Ub chain (ref. 54 and refs. therein). 
In one of possible models, the interaction of the 26S proteasome with a substrate-linked poly-Ub 
chain and the resulting delay in dissociation of the substrate from the proteasome would allow the 
ATP-dependent unfoldases of RP to unfold a previously structured region of the substrate and to 
insert it into the proteolytic chamber, thereby initiating processive proteolysis. An unfolded region 
could be, for example, the C-terminus or the N-terminus of substrate or, non-alternatively, an internal 
region, in which case it would be a hairpin loop whose insertion into the chamber would initiate 
processive proteolysis. The hairpin-insertion model of the proteasome-substrate interaction was 
suggested by us in 1989, and more explicitly in 1996. Fig. 11E illustrates the original model5,9,11, 
which was proposed before the structural understanding of RP, its poly-Ub-binding subunits and 
other aspects of the 26S proteasome.  
In this mechanism, an unstructured region of a substrate that encompasses its 
polyubiquitylated lysine may perform a ‘double’ duty of being important not only for 
polyubiquitylation but also for downstream, proteasome-mediated steps. A priori, it was also possible 
that the 26S proteasome might not strictly require an unstructured region in a substrate that had been 
captured through its poly-Ub chain, because unfoldases of RP might be able to initiate, efficiently 
enough, the ATP-mediated unfolding of a substrate (held by its poly-Ub chain) through thermal 
fluctuations alone, even in the absence of unstructured regions. Recent studies of N-degrons and 
other Ub-dependent degrons by the Matouschek, Jentsch, Dantuma, Coffino and other laboratories 
showed that the Ub-mediated protein degradation by the 26S proteasome does require the presence of 
an unstructured ‘initiation’ region in a substrate that has been captured by the proteasome through its 
poly-Ub chain. It was also shown that although the location of such a region in a polyubiquitylated 
substrate is not determined rigidly by the location of a branch point containing poly-Ub, the 
unstructured region should reside at an optimal distance from the branch point19,54,169,171-176.  
Thus the degradation, by the Arg/N-end rule pathway, of a protein containing an N-degron 
requires (i) the first determinant of N-degron, i.e., an N-terminal Ndp residue that can be recognized 
by a cognate E3 N-recognin (an Ndp residue is exposed by a proteolytic cut either directly or after 
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modifications of initially exposed Nds or Ndt residues); (ii) the second determinant of N-degron, i.e., 
a Lys residue(s), which functions as the site of formation of a poly-Ub chain and usually resides in an 
unstructured region of a substrate; and (iii) a sterically ‘suitable’ unstructured region (either the same 
region that encompasses the Ub attachment site or another region) that serves as the initiation site for 
the unfolding of a captured substrate by the 26S proteasome9,169. The latter requirement defines the 
third determinant of an N-degron. Yet another mechanistic aspect of N-degrons involves a complex 
of the chaperone-like ATPase Cdc48 (p97) with specific accessory proteins. This complex binds to 
several components of the Ub system, interacts with polyubiquitylated proteins ‘upstream’ of the 
26S proteasome, and facilitates protein degradation in ways that are incompletely understood177-179. 
Despite these and other complexities, an N-degron can be an efficacious and portable degradation 
signal, capable of conferring extremely short (1-2 min) in vivo half-lives on either newly formed or 
conformationally mature proteins4,9,21,24.  
It is likely (but remains to be verified) that the degradation of naturally unstructured 
(disordered) eukaryotic N-end rule substrates, while still requiring the targeting by a cognate 
N-recognin E3, may not require ubiquitylation. This possibility is made particularly likely by the 
previously demonstrated physical affinity of both the Ubr1 E3 (N-recognin) and its associated Ufd4 
E3 (Fig. 2A) for specific subunits of the 26S proteasome44,180,181. Another setting in which eukaryotic 
N-degrons may also act analogously to Ub-independent prokaryotic N-degrons is the previously 
analyzed Ubr1-mediated cotranslational degradation of N-end rule substrates as they are being made, 
i.e., directly at the ribosome139, apparently under conditions where the polypeptide chain that is being 
destroyed is targeted as a peptidyl-tRNA. The extent and mechanisms of the in vivo degradation of 
nascent proteins (i.e., of specific peptidyl-tRNAs) and newly formed (just completed) proteins, in 
comparison to degradation of the same proteins significantly after their synthesis21,24,139,182-185 is an 
extensively investigated but insufficiently understood subject. Given this problem’s spatiotemporal 
and technical complexity, definitive advances in such studies would be likely to require new 
methods. 
The understanding of degradation of N-end rule substrates by the Ub-independent bacterial 
Leu/N-end rule pathway (Fig. 5) is summarized in Fig. 12. It describes a detailed model proposed by 
Román-Hernandez et al.82 and based on studies by the Baker, Sauer, Bukau, Maurizi and other 
laboratories16,75,76,78,81,82. Most propositions of this model are supported by specific evidence, 
including crystal structures of ClpS, its mutant derivatives, and complexes of ClpS with peptide 
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mimics of N-end rule substrates73-75,79,186-189; crystal structures of ClpA and the ClpAP protease190-192; 
and single-molecule measurements of protein translocation and degradation by the ClpAP-like ClpXP 
protease193,194. The targeting begins when the ClpS N-recognin binds to an Ndp residue of an N-end 
rule substrate (with Kd of ~1 µM) and delivers the substrate to one of six ClpA subunits of the ClpAP 
protease. ClpAP consists of the ClpA6 unfoldase and the ClpP14 protease, in a complex that includes 
the axial pore in the ClpA6 hexamer that leads to the proteolytic chamber of the ClpA6-associated 
ClpP14 (Fig. 12). 
A substrate-bound ClpS monomer interacts with ClpA of the ClpA6 hexamer ~10-fold more 
tightly than free ClpS does82. This binding preference ‘solves’ the problem of competition between 
free and substrate-bound ClpS for ClpS-binding sites on ClpA6. In addition, the interaction between 
ClpS and ClpA6 exhibits negative cooperativity, i.e., only one molecule of ClpS binds to ClpA6 with 
high affinity78. The 12-kDa ClpS consists of the flexible N-terminal (Nt) extension and the folded 
core domain, which binds to an N-degron (the N-terminal Ndp residue) of an N-end rule substrate 
(Fig. 6B-D). The substrate-bound ClpS interacts with ClpA at the N-domain of ClpA. This domain is 
connected to the rest of ClpA by a flexible linker region. A key feature of the model is a conversion 
of the initial ‘low-affinity’ ternary complex (Fig. 12A) to a ‘high-affinity’ delivery complex 
(Fig. 12B, C), in which a part of the previously free Nt-extension of ClpS becomes bound to the 
ClpA6 axial pore (near its entrance), thereby initiating the transfer of the ClpS-bound N-end rule 
substrate (its N-degron) from ClpS to a region inside the ClpA6 pore. Previous evidence (ref. 195 and 
refs. therein) suggests that this region of the ClpA6 pore exhibits a ClpS-like (but significantly 
weaker) affinity for a bulky hydrophobic (Ndp) N-terminal residue. In the resulting arrangement, a 
conformational change of ClpA, fueled by ATP hydrolysis, pulls on the pore-bound Nt-extension of 
ClpS, perturbs the conformation of the core domain of ClpS and thereby both weakens its binding to 
N-degron of a substrate and facilitates the transfer of substrate (its N-degron region) from ClpS to a 
site in the ClpA6 pore (Fig. 12C, D). As is also the case with eukaryotic N-end rule substrates, 
‘optimal’ substrates of the bacterial Leu/N-end rule pathway contain features that are additional to the 
presence of a bulky hydrophobic N-terminal residue. These features include an unstructured region 
near the N-terminal destabilizing residue, an under-representation of acidic residues in that region, 
and a stretch of 2-3 hydrophobic residues 6-12 residues from the substrate’s N-terminus72,76,77. 
One experimentally supported assumption of the model is the possibility of more than one 
polypeptide chain occupying the pore of a ClpA-type unfoldase at the same time196,197 (Fig. 12C). 
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Another aspect of the model82 is resistance of the folded core of the ClpA-bound ClpS to unfolding 
by the ATP-fueled pull on the Nt-extension of ClpS (Fig. 12C). This resistance, accompanied by a 
conformational perturbation of ClpS, prevents degradation of the Nt-extension and the rest of ClpS, 
and in addition facilitates the dissociation of ClpS from ClpA, thereby leaving the Ndp residue 
(N-degron) of the substrate inside the pore and completing the targeting cycle (Fig. 12D). Motor 
proteins operate through power strokes, through a biased Brownian motion (Brownian ratchet), or 
through a combination of these mechanisms193,198-200. Experimental evidence favors a mechanism of 
the ClpA6 motor that relies predominantly on a power stroke193,194. Once the N-terminal region of an 
N-end rule substrate is brought inside the pore of the ClpA6 motor (Fig. 12C, D), the ATP-dependent, 
presumably cyclic conformational changes of the pore region lead to a stepwise propulsion of the 
polypeptide chain of a captured substrate (accompanied by its unfolding) into the proteolytic chamber 
of the ClpA6-associated ClpP14. The result is processive degradation of the substrate to short 
peptides16,75,76,78,81,82. 
Ub-lacking proteolytic circuits such as, for example, the bacterial Leu-N-end rule pathway 
(Fig. 5, Fig. 6 and Fig. 12) are significantly less complicated, composition-wise and apparently also 
mechanism-wise, than Ub-dependent degrons and the targeting/degradation machinery in eukaryotes. 
The remarkable complexity (including compositional complexity) of the Ub system begs the question 
of how prokaryotes, which are obviously sophisticated about processive proteolysis200,201, get by 
largely without Ub and ubiquitylation. Both bacteria and archaea have proteins that are spalogous 
(spatially similar1) to Ub in that they contain the β-grasp Ub fold202. Most archaea and some bacteria 
contain proteolytic pathways that involve conjugation of Ub-like proteins to other proteins66-70,203-207. 
However, a large fraction of processive proteolysis in extant bacteria does not appear to be mediated 
by Ub-like pathways. For example, in the bacterial Leu/N-end rule pathway the ClpS N-recognin 
binds to N-end rule substrates and delivers them to the ClpAP protease for processive degradation 
without involving a ubiquitylation-like mechanism (Fig. 5 and Fig. 12).  
One possibility is that the mechanistic complexity of the eukaryotic Ub system stems, at least 
in part, from its additional capabilities that are required in eukaryotes but not in prokaryotes. For 
example, some features of the subunit-selective proteolysis by the Ub system that are physiologically 
important in eukaryotes (Section 9.4) might not be necessary in bacteria13,168,208. This conjecture 
remains to be verified. In addition, the ER-associated degradation (ERAD) of proteins that travel 
through or reside in the secretory pathway is functionally essential and Ub-mediated in 
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eukaryotes52,59,63,209 but a counterpart of this process in bacteria is Ub-independent. Specifically, 
bacteria employ sophisticated protein quality-control pathways in the periplasmic space (analogous to 
the ER lumen in eukaryotes) but do not appear to use ubiquitylation-like mechanisms. 
It is also possible that an aspect of folding of some eukaryotic proteins (versus the presumed 
absence of such proteins in bacteria) presents a sufficient challenge to the eukaryotic 26S proteasome 
to require devices such as poly-Ub chains and associated machinery for destruction of such proteins. 
In other words, the Ub/proteasome-mediated processive proteolysis may have a greater 
protein-unfolding ‘power’ than analogous mechanisms that lack polyubiquitylation. This conjecture 
is not precluded but is unlikely to a be a sufficient explanation, in part because the degradation of one 
and the same N-end rule substrate can be shown to be Ub-dependent in eukaryotes but Ub-
independent in bacteria14. Specifically, Arg-eK-β-galactosidase (Arg-eK-βgal) is an engineered 
~110-kDa (as a monomer) N-end rule substrate derived from E. coli βgal (LacZ) and produced, using 
the Ub fusion technique (Fig. 1B), through the cotranslational in vivo deubiquitylation of 
Ub-Arg-eK-βgal4,9,21,24. Arg-eK-βgal bears N-terminal Arg, an Ndp residue in eukaryotes and an Nds 
residue in bacteria (Fig. 2A and Fig. 4). Arg-eK-βgal also contains, between N-terminal Arg and the 
βgal moiety, a ~40-residue region termed eK [extension (e) containing lysine (K)]. The apparently 
unstructured eK extension9,21,24 has the technically valuable property of lacking internal degrons while 
containing two ‘ubiquitylatable’ Lys residues, Lys15 and Lys17. Arg-eK-βgal is polyubiquitylated and 
short-lived in S. cerevisiae, provided that its eK extension contains at least one of these two lysines. 
Specifically, Arg-e∆K-βgal, in which both Lys15 and Lys17 were converted to (non-ubiquitylatable) 
Arg residues, is long-lived in S. cerevisiae, despite the presence of the N-terminal Arg residue9,24. In 
contrast, both Arg-eK-βgal and Arg-e∆K-βgal are degraded at similar rates by the E. coli Leu/N-end 
rule pathway14. Thus at least in this case, the ubiquitylation/proteasome machinery of eukaryotes 
‘imposes’ the requirement of ubiquitylation that is unnecessary in bacteria, vis-á-vis the same 
reporter protein. 
Yet another, non-alternative possibility is that the Ub system might have indeed been 
‘overdesigned’ in the course of eukaryotic evolution, i.e., that bacterial-type mechanisms, with fewer 
components and without extensive use of ubiquitylation, can accomplish what the Ub system does. 
An overdesign might have happened for reasons, suggested by Lynch210, that are generally relevant to 
evolution of eukaryotes. A population genetics-based argument can be made that many aspects of 
molecular circuits in eukaryotic cells have evolved, at least initially, through a quasi-random, 
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recurrent genetic drift. The relative importance of evolution by this route (as distinguished from 
adaptive Darwinian evolution through positive selection) depends on the breeding system of a 
species, on the organization of its genome, and on its history of long-term population bottlenecks. A 
small population size is likely to have been a recurrent characteristic of early eukaryotic evolution, at 
the time of emergence of a ‘stem’ eukaryote, roughly 1.5 billion years ago. Most new alleles of a 
genetic locus are deleterious. The probability of fixation of a new allele (vis-à-vis the probability of 
its disappearance from a population) is higher in a smaller populaton210. Under such conditions, 
complicated circuits might have evolved, to a significant extent, through occasional fixations of 
mildly deleterious mutations that were eventually ‘compensated’ by suppressor mutations that often 
had their own fitness costs and were compensated by yet additional suppressors. 
In sum, complexity in designs of biological circuits is not always a sign of adaptive evolution 
alone, because complexity can also result from a recurrent, long-term, sometimes deleterious genetic 
drift. (The relatively large sizes and numbers of introns in mammals, vis-à-vis much lower sizes and 
numbers of introns in fungi and their absence in prokaryotes are one example of evolution, in 
multicellular eukaryotes, that is partially drift-based and population size-dependent210.) The history of 
a species contains, in differing proportions, both a drift mode and an adaptive (Darwinian) mode. The 
population sizes of prokaryotes are (and were) vastly larger than those of eukaryotes, indicating that 
populations of prokaryotes are much more resistant than eukaryotes to evolutionary changes that stem 
from genetic drift, as distinguished from positive selection210. If the primordial Ub system emerged 
initially to a large extent through a genetic drift, this would account, at least in part, for the absence of 
the bona fide Ub system in extant prokaryotes. The S. cerevisiae and human Ub systems are 
remarkably similar, differing mostly by a larger number of human E3 Ub ligases and associated 
machinery. Thus the design of the Ub system must have reached its essentially modern state in early 
eukaryotes, before the separation of fungal and animal lineages. In sum, although an adaptive 
Darwinian evolution undoubtedly played a major role in making the extant Ub pathways what they 
are, it is likely that the Ub system emerged and became ‘entrenched’ in primordial eukaryotes to a 
large extent through a genetic drift unaccompanied (at the beginning) by a significant positive 
selection80, a general pattern of evolution discussed by Lynch210. 
Because an N-degron consists of several determinants, subunit-selective polyubiquitylation 
and degradation of an oligomeric protein can occur not only in cis (with all determinants of an 
N-degron in the same polypeptide chain) but also in trans13 (Fig. 11B, C). In the resulting 
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subunit-selective protein degradation, discovered in 1990 in the context of the Arg/N-end rule 
pathway and found to be characteristic of the entire Ub system as well, a destabilizing N-terminal 
residue of one protein subunit can be engaged by an N-recognin to direct selective degradation of 
another subunit in the same oligomeric protein13. This capability makes possible protein remodeling, 
a major functional attribute of the Ub system. Regulatory circuits wield subunit-selective proteolysis 
for either positive or negative control, including transitions in the cell cycle, the control of 
transcription and DNA replication, and many other processes. Among specific examples are the 
activation of a major transcription factor NF-κB, through the degradation of its inhibitory subunit 
IκB, and the inactivation/alteration of cyclin-dependent kinases (which drive the cell cycle) through 
the subunit-selective degradation of their cyclin subunits211,212. Matouschek and colleagues have 
shown that the location and properties of an unstructured region of a protein substrate that serves as 
the proteasome-initiation site can determine which subunit is degraded19,168. For example, a 
polyubiquitylated subunit of an oligomeric protein that is delivered to the 26S proteasome via its 
poly-Ub chain can be resistant to degradation and direct the subunit-selective destruction of a 
non-ubiquitylated subunit in the same oligomeric protein168. In the cited study, this trans-degradation 
effect168 was demonstrated with substrates of the Ub-fusion degradation (UFD) pathway (see 
Section 9.1). Given the likely generality of this mechanism, Fig. 11D illustrates the (hypothetical) 
possibility of a trans-degradation of this kind for an oligomeric substrate of the N-end rule pathway. 
Another important property of N-end rule circuits is exemplified by the S. cerevisiae Ubr1 E3 
N-recognin. The 225 kDa Ubr1 (Fig. 7A) contains at least four substrate-binding sites. Two of them 
recognize specific N-degrons, whereas the other sites recognize internal (non-N-terminal) degrons. 
The occupancy of Ubr1 sites that recognize N-degrons has been shown to regulate, in physiologically 
relevant ways, the activity of another binding site of the Ubr1 N-recognin27,29,38-40 (Section 9.4). The 
multiplicity of substrate-binding sites in Ubr1 and their allosteric dependencies are likely to recur in 
other E3 N-recognins as well. 
 
7. Applications of the ubiquitin fusion technique and N-degrons 
The Arg/N-end rule pathway (Fig. 2A) was discovered through the invention of the Ub fusion 
technique4,9 (Fig. 1B). This strategy was later employed to identify the bacterial Leu/N-end rule 
pathway as well, via expression of the yeast Ubp1 deubiquitylase in E. coli14. The Ub fusion 
technique is still the method of choice for expressing, in vivo, a protein of interest that bears a desired 
Page 23 of 98
John Wiley & Sons
Protein Science
24 
 
N-terminal residue20,24,213 (Fig. 1B). Over the last two decades, this approach gave rise to several 
‘descendant’ technologies, in the Ub field and beyond6,139,213-219. One example is a heat-activated, 
portable N-degron that allows construction of temperature-sensitive (ts) variants of specific proteins 
without changing their amino acid sequences216,220. Another example is the Ub sandwich assay, in 
which a linear fusion of three reporter domains that bears N-terminal Ub as well as Ub moieties 
between the domains is designed to detect and measure cotranslational protein degradation in living 
cells139. Yet another technique, the Ub translocation assay (UTA), employs Ub fusions that contain 
N-terminal signal sequences to probe kinetic aspects of protein translocation across membranes 
in vivo217. In 1994, Johnsson and I developed a method, later termed the protein fragment 
complementation assay (PCA), that detects protein interactions through the conditional in vivo 
reconstitution of a single-domain protein from its fragments218. The first in vivo PCA involved a 
split-Ub design in which two halves of a mutant Ub moiety were configured as sensors of interactions 
between two proteins of interest that were linked to Ub halves218,221. The split-Ub PCA led to other 
useful PCAs by other laboratories, including split GFP (green fluorescent protein), split DHFR, and 
split β-lactamase (refs. 222-225 and refs. therein). 
The Ub fusion technique also led to the concept of signal regulated, cleavage-mediated toxins 
(sitoxins), in which an initially short-lived (or otherwise down-regulated) toxin is activated through a 
cleavage (e.g., by a viral protease in a virus-infected cell) that removes a degron or activates a toxin 
otherwise, thereby increasing the level of active toxin226. Variants of this strategy were employed by 
others to develop protein-based conditional reagents, including antiviral drugs227-233. Muir and 
colleagues combined a version of the sitoxin approach226 with the split-Ub PCA method218 to develop 
the SURF (split Ub for the rescue of function) technique, in which a protein of interest that is made 
short-lived in vivo through a link to a portable degron can be metabolically stabilized by a small 
compound that causes a cleavage-mediated removal of degron234. Using mouse DHFR as a reporter, 
we showed that the Ub-dependent proteolysis of a degron-bearing protein can be slowed down or 
halted through the addition of a compound (e.g., methotrexate, a tight-binding DHFR inhibitor) that 
increases thermodynamic stability of a protein235,236. Wandless and colleagues employed this 
approach, using E. coli DHFR and its inhibitor trimethoprim, to develop a method for regulating 
protein degradation in cultured mammalian cells and intact animals, including their neurons237. 
Another recent technique uses a conditionally expressed viral TEV protease to cleave, in vivo, a 
protein of interest that had been engineered to contain a TEV cleavage site at a desired position238. 
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This method makes it possible, among other things, to create an N-degron posttranslationally, as 
distinguished from the cotranslational production of N-degrons through the Ub fusion technique4,9,213. 
 
8. The Ac/N-end rule pathway 
The Ac/N-end rule pathway3 (Fig. 2B and Fig. 4A) was discovered 24 years after the 
Arg/N-end rule pathway4 (Fig. 2A). In S. cerevisiae, AcN-degrons of the Ac/N-end rule pathway are 
recognized by the Doa10 E3 Ub ligase3 and apparently by other E3s as well (C.-S. Hwang, 
A. Shemorry and A.V., unpubl. data). The 151-kDa RING-type Doa10 E3 is a multispanning integral 
membrane protein located in the endoplasmic reticulum (ER) membrane and in the inner nuclear 
membrane239-241. The Doa10 E3 functions together with the Ubc6 and Ubc7 E2 enzymes, and targets 
both ‘soluble’ (nuclear and cytosolic) and transmembrane proteins3,242. Isolated S. cerevisiae Doa10 
selectively binds to the Nt-acetylated N-terminal Met, Ala, Val, Ser, Thr, Cys, Gly and Pro residues 
of model peptides3. Remarkably, the binding of Doa10 to Nt-acetylated residues of these peptides is 
precluded by the presence of a basic residue such as Lys at position 2 (ref. 3). Thus the S. cerevisiae 
Ac/N-end rule pathway avoids the targeting of proteins with a basic residue at position 2 through two 
independent constraints: first, such proteins are not Nt-acetylated in yeast91,92; and second, the 
cognate Doa10 E3 apparently does not recognize Nt-acetylated proteins that bear a second-position 
basic residue3. Evolutionary and mechanistic reasons for a ‘double’ filter against potential substrates 
of this class are unclear at present, because the absence of Nt-acetylation of such proteins in 
S. cerevisiae should suffice. Mammalian E3s that are sequelogous (similar in sequence1) to 
S. cerevisiae Doa10 include the human TEB4 E3 Ub ligase243. This and other evidence (C.-S. Hwang, 
B. Wadas and A.V., unpubl. data) indicate the presence of the Ac/N-end rule pathway in multicellular 
eukaryotes as well. 
Nt-acetylation is largely cotranslational, apparently irreversible, and involves a majority of 
cellular proteins. What functions are subserved by such a massive production of degradation signals 
(AcN-degrons) in nascent proteins, if many of these proteins are destined for long half-lives? We 
suggested that a major role of these degradation signals involves quality-control mechanisms and the 
regulation of protein stoichiometries in a cell3. A key feature of such mechanisms would be 
conditionality of AcN-degrons. If a nascent Nt-acetylated protein can fold its N-terminal domain 
rapidly enough, or if this protein interacts with a ‘protective’ chaperone such as Hsp90, or becomes 
assembled into a cognate multisubunit complex, the cotranslationally created AcN-degron of this 
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protein may become inaccessible to a cognate Ub ligase such as Doa10. Consequently, this 
Nt-acetylated protein would not be targeted for degradation via its AcN-degron. In contrast, delayed or 
defective folding of a protein’s N-terminal domain (because of oxidative, heat or other stresses; or a 
conformation-perturbing mutation; or nonstoichiometric levels of cognate protein ligands) would 
keep an AcN-degron exposed (active) and thereby would increase the probability of the protein’s 
destruction. 
Might the conditionality of AcN-degrons underlie the regulation of protein assembly into 
multiprotein complexes? For example, histones and ribosomal proteins tend to be short-lived until 
they become integrated into larger assemblies, the nucleosomes (in chromosomes) and the ribosomes, 
respectively244,245. Selective degradation of these proteins in their unassembled states makes possible 
the regulation of their levels vis-á-vis the rates of their production through transcription and 
translation. Little is known about degrons of ribosomal proteins or histones that mediate their 
conditional degradation. At the same time, most histones and ribosomal proteins are 
Nt-acetylated91,92. We suggested that the regulation of in vivo protein stoichiometries in oligomeric 
proteins and nucleoproteins (including chromosomes and ribosomes) through the assembly-controlled 
protein degradation may be mediated, to a large extent, by AcN-degrons that form cotranslationally 
and are accessible to a cognate Ub ligase in ‘free’ proteins but not in their ‘assembled’ counterparts3. 
Aneuploidy, in which the chromosome number in a cell is not an exact multiple of the haploid 
number, is a frequent property of cancer cells and a cause of birth defects such as Down syndrome 
(a trisomy of chromosome 21). Physiological defects in aneuploid cells are likely to be caused, at 
least in part, by maladaptive molar ratios of newly formed proteins in such cells, given their 
deviations from wild-type gene dosages on over-represented or under-represented chromosomes. 
Homeostatic responses in such cells would have to destroy a higher than normal load of unassembled 
proteins. This may account for the known hypersensitivity of aneuploid cells to proteasome 
inhibitors246. If so, and if AcN-degrons contribute to proteolysis that regulates in vivo protein 
stoichiometries, aneuploid cancer cells may prove to be hypersensitive to inhibition of the Ac/N-end 
rule pathway, a mode of therapy that would be more selective than proteasome inhibitors, which 
down-regulate the Ub system at large. 
Nonlinear effects of in vivo protein degradation are a rule rather than exception. For example, 
if a homodimeric protein is significantly longer-lived in vivo in comparison to its monomer subunit 
(because a degron accessible in a monomer becomes buried or otherwise less active in a dimer), the 
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steady-state concentration of this protein in a cell can be a strongly nonlinear (sigmoid) function of 
the rate of its synthesis. Such effects would occur with both homooligomers and heterooligomers. In 
what follows, I mention a potentially important aspect of this disposition that has not been pointed 
out previously, to my knowledge. Specifically, one should expect, in aneuploid and other 
‘disbalanced’ settings, a major difference in physiological outcomes for homooligomers versus 
heterooligomers. Consider, for example, an aneuploid cell that overproduces at least some proteins 
from its over-represented chomosome. If a specific overproduced protein forms a heterodimer with a 
protein encoded by another chromosome that is present at the normal dosage, an excess of 
overproduced protein would have its degron, e.g., an AcN-degron, exposed (active) and would be 
preferentially destroyed by the Ac/N-end rule pathway. As a result, the in vivo concentration of this 
overexpressed protein would be at most marginally higher than it would have been in the absence of 
aneuploidy. By contrast, if an overproduced protein forms a homodimer (or a homooligomer) in 
which an AcN-degron is inactive (sterically shielded), the Ac/N-end rule pathway would be unable to 
‘detect’ an overexpression of this (self-associated) protein, with the consequent failure of 
proteolysis-based compensatory mechanisms. The same argument applies to degradation signals 
distinct from AcN-degrons, as long as a degron is rendered inactive (or less active) through the 
formation of a homooligomeric protein. This argument can also apply if a heterodimer is formed 
from subunits encoded by the same over-represented chromosome. In sum, it is possible (this 
conjecture remains to be verified) that fitness-reducing effects of aneuploidy stem, to a significant 
degree, not only from a disbalanced (non-stoichiometric) production of proteins, but also specifically 
from the impossibility, for an otherwise protective proteolytic circuit, to ‘detect’ an overproduction of 
proteins that form homooligomers. 
The irreversibility of Nt-acetylation may underlie a putative role of AcN-degrons in the 
degradation of relatively long-lived intracellular proteins, with half-lives of many hours or days. The 
initial burst of degradation, through an AcN-degron, of some among the molecules of a newly formed, 
not yet ‘assembled’ Nt-acetylated protein is followed by the formation of a cognate oligomeric 
complex in which the protein’s AcN-degron becomes inactive (sterically shielded). Whether or not 
this AcN-degron is activated (becomes accessible) later would be determined by the probability of 
dissociation of the complex over time, either a spontaneous dissociation or an ‘induced’ one. The 
latter can be caused, for example, by a physiologically relevant phosphorylation of the complex, or 
by events such as heat or oxidative stress. The resulting transient accessibility of the (now exposed) 
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AcN-degron of a protein would immediately and strongly increase the probability of the protein’s 
destruction, until the cognate complex can reassemble and thereby again protect the protein. In 
contrast to the notion of a low and time-invariant probability of destruction of a long-lived protein, 
the above model posits recurrent transitions between at least two states. In one state, the probability 
of protein’s destruction is high (AcN-degron is exposed). In the other state, in which the protein is a 
part of a complex, the probability of protein’s destruction is low or negligible. The kinetics of 
reversible transitions between these states and the probability of protein’s destruction in the 
(transient) absence of protective complex would determine, together, an experimentally measured 
in vivo decay curve of such a protein. Thus an apparently first-order degradation kinetics may be 
result, mechanistically, from transitions between different structural states of a protein and different 
probabilities of degradation. This model, which remains to be verified for AcN-degrons, is relevant to 
other degrons as well. 
In the recently determined crystal structure, by the Barford laboratory, of a complex between 
the Hcn1 and Cut9 subunits of the yeast Schizosaccharomyces pombe APC/C Ub ligase, the 
Nt-acetylated Met residue of Hcn1 was found to be enclosed within a chamber created by the Cut9 
subunit247 (Fig. 13). The authors interpreted this result as a likely example of the assembly-mediated 
shielding of AcN-degrons3. Although Protein Data Bank (PDB) and other databases of protein 
structures contain thousands of proteins, the Hcn1-Cut9 complex247 is one of very few (< 10) 
structures that show details of a protein-bound Nt-acetylated residue. Another structure of a complex 
with a known spatial location of Nt-acetylated N-terminus contains the tandem PHD1/2 finger (a part 
of the human DPF3b chromosomal protein) that is bound to the Nt-acetylated peptide of histone H4 
(residues 1-22) and specifically interacts with several residues of this H4 peptide, including its 
Nt-acetylated Ser1 residue248. The paucity of such structures in current databases stems from often 
unstructured N-terminal regions of studied proteins, from frequent N-terminal truncations of proteins 
(to facilitate their crystallization), and from the still prevalent use, for crystallization, of eukaryotic 
proteins expressed in bacteria, in which Nt-acetylation is not efficacious. Hcn1-Cut9 and analogous 
complexes in which the shielding of specific Nt-acetylated N-termini can be demonstrated at a 
near-atomic resolution247, can now be used to explore physiological functions of AcN-degrons. 
For reasons described above, AcN-degrons comprise the most prevalent class of specific 
degradation signals in cellular proteins3 (Fig. 2B and Fig. 4). Although the Nt-acetylation of cellular 
proteins by ribosome-associated Nt-acetylases is largely cotranslational89,95, the (currently unknown) 
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molar concentrations of specific Nt-acetylases in vivo are likely to be significantly lower than the 
molar concentration of ribosomes. This, and the inherent stochasticity of cotranslational enzymatic 
reactions make it virtually certain that Nt-acetylation of proteins is less than quantitative in most 
cases. Indeed, many proteins are known to be incompletely Nt-acetylated91,110, despite the existence 
of posttranslational Nt-acetylation (J.-H. Oh and A.V., unpubl. data). The latter may not be able to 
compensate for the incompleteness of cotranslational Nt-acetylation because of rapid formation of 
cognate complexes in which the N-termini of proteins, either Nt-acetylated (Fig. 13) or unacetylated, 
would become sterically inaccessible. Given this and other aspects of Nt-acetylation, the emerging 
field of the Ac/N-end rule pathway may prove to be a source of new answers to several outstanding 
questions. For example, the phenomenon of proteotoxicity might stem, in part, from the incomplete 
Nt-acetylation of normally expressed proteins91-93,102 and the resulting presence, in a cell, of 
otherwise identical protein molecules that either lack or contain an AcN-degron. Given this 
possibility3 and putative functions of AcN-degrons, the Ac/N-end rule pathway may also play a role in 
processes that alter the rate of cellular and organismal aging. 
 
9. The Arg/N-end rule pathway 
The Arg/N-end rule pathway involves the Nt-arginylation of N-end rule substrates and also 
the targeting of specific unmodified N-terminal residues by UBR-type E3 N-recognins, which can 
recognize not only N-degrons but also internal (non-N-terminal) degrons (Fig. 2A and Fig. 3). 
Despite their broad range, the known functions of the Arg/N-end rule pathway (Section 3) are still the 
tip of the iceberg. Some of these functions are understood, in part, both physiologically and 
mechanistically (Section 9.4), but many roles of the Arg/N-end rule pathway were discovered 
through genetic approaches and therefore remain to be explicated in terms of specific substrates and 
mechanisms. The known physiological substrates of the Arg/N-end rule pathway are the beginning of 
a much longer list. It already contains a number of putative (unverified) substrates and may require 
new methods for its systematic elucidation (Section 5 and Fig. 10). 
 
9.1. The double-E3 design of the Arg/N-end rule pathway 
Until recently, polyubiquitylation of substrates by the S. cerevisiae Arg/N-end rule pathway 
was thought to be mediated by a dimer comprising the 225-kDa Ubr1 E3 and the Ubr1-bound 20-kDa 
Rad6 E2 enzyme5,6,38,39,249. In 2010, it was discovered that the targeting ensemble is more elaborate. 
It comprises a physical complex of the RING-type Ubr1 E3 (N-recognin) and the HECT-type Ufd4 
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E3, in association with their cognate E2s Rad6 and Ubc4/Ubc5, respectively40,44 (Fig. 2A). Ufd4 is 
the 168 kDa HECT-type E3 of the Ub-fusion degradation (UFD) pathway that recognizes a 
‘nonremovable’ N-terminal Ub moiety of a Ub fusion as a primary degron and polyubiquitylates the 
Ub moiety, a prerequisite for the fusion’s degradation by the 26S proteasome180,181,250-255. The UFD 
pathway was discovered through analyses of N-terminal Ub fusions in which an alteration of either 
the Ub moiety or a junctional amino acid residue inhibits the cleavage of a fusion by deubiquitylases 
and thereby results in the fusion’s degradation by the UFD pathway4,250,256,257. The UFD pathway is 
present in both yeast and mammals258, suggesting that the Ubr1-Ufd4 double-E3 organization of the 
S. cerevisiae Arg/N-end rule pathway is universal among eukaryotes44. 
Ufd4 is not an N-recognin, i.e., it does not, by itself, recognize N-degrons, in contrast to Ubr1. 
However, through its physical interaction with the Ubr1 E3 (Fig. 2A) , the Ufd4 E3 functions as a 
novel component of the Arg/N-end rule pathway that increases the efficacy of Ubr1, at least in part 
by augmenting the processivity of polyubiquitylation of N-end rule substrates44. The function of Ufd4 
in the Arg/N-end rule pathway is not confined to processivity enhancement, as Ufd4 can also 
recognize the internal degron of the Mgt1 DNA repair protein (a substrate of the Arg/N-end rule 
pathway) even in ubr1∆ cells40, i.e., in the absence of Ubr1. Thus the sets of internal degrons 
recognized by Ubr1 and Ufd4 are partially overlapping. Although Ufd4 is not strictly essential for the 
ability of Ubr1 to mediate the Arg/N-end rule pathway, this pathway is detectably impaired in ufd4∆ 
cells44. 
Earlier studies introduced the operationally defined concept of an E4 as an E3-like enzyme 
that cooperates with substrate-specific ubiquitylation machinery to increase the efficacy (including 
processivity) of polyubiquitylation, and in some cases alters topology of a growing poly-Ub chain, 
i.e., the locations of Gly-Lys isopeptide bonds between the adjacent Ub moieties in a chain257,259-261. 
Remarkably, the increased processivity of the Ubr1-dependent polyubiquitylation of N-end rule 
substrates by the Ubr1-bound Ufd4 Ub ligase44 is ‘reciprocated’ in the context of the UFD pathway. 
Specifically, the Ufd4-bound Ubr1 Ub ligase increases the processivity of polyubiquitylation of UFD 
substrates44. Thus, operationally, the complex of Ubr1 and Ufd4 (Fig. 2A) functions as an E3-E4 pair 
in which the ‘assignment’ of an E3 or E4 function depends on a substrate and the nature of its degron. 
It was also found that Ubr1, similarly to Ufd4, contains a domain that specifically binds to the 
N-terminal Ub moiety of protein fusions but not to free Ub, indicating that Ubr1 can target UFD 
substrates independently of the Ufd4 Ub ligase44. Because Ubr1 is apparently ~10-fold less abundant 
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than Ufd4 in wild-type yeast44, the ‘double’ E2-E3 Ubr1/Rad6-Ufd4/Ubc4 complex is expected to 
mediate the bulk of the Arg/N-end rule pathway (Fig. 2A), whereas the same complex mediates only 
a part of the UFD pathway. In vitro, Ubr1 and Ufd4 bind, separately and independently, to specific 
(partially overlapping) sets of subunits of the 26S proteasome180. Now that the proteasome-binding 
in vivo entity turned out to be, most likely, the Ubr1-Ufd4 complex (with associated E2 enzymes), it 
is possible that the targeting of N-end rule and UFD substrates is mediated, at least in part, by this 
complex that is ‘pre-bound’ to the 26S proteasome. These are just some of the ramifications of the 
discovery of the Ubr1-Ufd4 complex, a functional and mechanistic advance that unified two 
proteolytic systems that have been studied separately for two decades44. 
Purified S. cerevisiae Ubr1 binds to either type-1 (basic) or type-2 (bulky hydrophobic) 
destabilizing N-terminal residues of 11-residue peptides with a Kd of ~1 µM, whereas no binding 
(Kd > 0.1 mM) was observed with otherwise identical peptides bearing the N-terminal Gly 
residue38,43. Crystal structures of the ~80-residue UBR domains (type-1 binding sites) of S. cerevisiae 
Ubr1 and its mammalian counterpart have been determined (Fig. 8A, B)83-85, but no structural 
information is available about the type-2 binding site, let alone the entire ~200-kDa mammalian or 
yeast Ubr1, despite crystallization attempts by more than one laboratory. The discovery of interaction 
between the Ubr1 and Ufd4 E3s suggests that their complex44 might be easier to crystallize than its 
individual components. Although the type-1 and type-2 binding sites are adjacent in S. cerevisiae 
Ubr1 (Fig. 7A), a screen for mutations in UBR1 that inactivate one but not the other binding site has 
readily yielded Ubr1 mutants with such properties38, suggesting a structurally autonomous folding not 
only of the type-1 (UBR) domain (Fig. 8A, B) but of a type-2 domain as well. 
A spatial proximity of the type-1 and type-2 binding sites of Ubr1 was made use of in 
designing a bivalent inhibitor of the N-end rule pathway that was expected to bind simultaneously to 
both of these sites and therefore to exhibit a higher efficacy than a ‘monovalent’ inhibitor. In a 
proof-of-principle study, a tetramer of X-βgal, produced from Ub-X-βgal (Fig. 1B; X=Arg or Leu), 
was produced as a set of homotetramers and heterotetramers by coexpressing, in S. cerevisiae, 
Arg-βgal (a type-1 N-end rule substrate) together with Leu-βgal (a type-2 N-end rule substrate)262. 
These engineered proteins contained a ~40-residue extension between N-terminal residue and the 
βgal moiety. This sequence, termed the e∆K extension (see Section 6), lacked Lys residues, and the 
first 200 residues of the βgal moiety also lacked lysines. As a result, these βgal-based reporters were 
long-lived in vivo, despite their destabilizing N-terminal residues9,24,213. In the 3D structure of E. coli 
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βgal, two of its N-termini (with the other pair of N-termini on the opposite side of the tetramer) are 
spatially close and oriented in the same direction263. This spatial feature of βgal and the above design 
resulted in some of expressed X-βgal tetramers being heterotetramers in which two flexible, adjacent 
N-terminal regions contained the N-terminal Arg and Leu residues262. It was found that these 
‘bivalent’ Arg/Leu-βgal heterotetramers inhibited the degradation of reporter N-end rule substrates in 
S. cerevisiae much more efficaciously than either Arg-βgal alone or Leu-βgal alone262. An inhibitor 
of this kind acts as a competitive inhibitor of the type-1/2 sites of N-recognins and may also act, at 
the same time, as an allosteric activator of other substrate-binding sites of N-recognins, the ones that 
bind to internal (non-N-terminal) degrons of specific regulatory proteins. The latter inference 
(it remains to be verified for macromolecular-size inhibitors) stems from the known allosteric 
activation, by dipeptides with destabilizing N-terminal residues, of the autoinhibited third substrate-
binding site of yeast Ubr1, the site that targets the internal degron of the Cup9 transcriptional 
repressor (Fig. 15 and Section 9.4). The Kwon laboratory has further advanced the bivalent-inhibitor 
approach by producing and characterizing small (< 1 kDa) synthetic heterovalent inhibitors of the 
N-end rule pathway264. 
In contrast to S. cerevisiae, in which Ubr1 is the sole N-recognin of the Arg/N-end rule 
pathway, the genome of a multicellular eukaryote, e.g., a mammal, encodes at least four UBR 
domain-containing E3 N-recognins, termed Ubr1, Ubr2, Ubr4, and Ubr5 (also called Edd)15,31,43 
(Fig. 8C). Sequelogs1 of the 570-kDa mouse Ubr4 N-recognin are known as PUSHOVER in 
D. melanogaster and as BIG in plants15,31,265-269. Mammalian Ubr1 and Ubr2 are highly sequelogous 
N-recognins (they are also sequelogous to S. cerevisiae Ubr1), whereas the sequelogy between, e.g., 
Ubr1 and either Ubr4 or Ubr5/Edd is largely confined to their ~80-residue UBR domains. Mutational 
inactivation of human UBR1 causes Johanson-Blizzard syndrome (JBS) (Sections 3 and 9.4), and 
Ubr1-/- mice exhibit aspects of JBS as well34. Mice lacking Ubr2 have a variety of defects, including 
genomic instability and impaired spermatogenesis (and infertility) in males30,123. One function of 
mouse Ubr2 in meiotic spermatocytes is ubiquitylation of histone H2A, in a setting where this 
modification plays a role in transcriptional silencing270. In contrast to viability of single-mutant 
Ubr1-/- and Ubr2-/- mice, double-mutant mouse strains that lacked both Ubr1 and Ubr2 died as 
~11-day (midgestation) embryos, with major defects in neurogenesis and cardiovascular 
development271.  
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Mammalian Ubr1, Ubr2 and Ubr4 N-recognins contain both type-1 and type-2 
substrate-binding sites, whereas the Ubr5/Edd N-recognin lacks the type-2 binding site31 (Fig. 8C). 
Thus, in agreement with findings by the Bachmair laboratory about plant N-recognins18,272,273, a 
mammalian N-recognin can contain both type-1 and type-2 substrate-binding sites or just one of 
them. The presence of a UBR domain in an E3 Ub ligase signifies its N-recognin property (i.e., its 
ability to bind to N-terminal Ndp residues of proteins or short peptides; Fig. 3) only in some cases, as 
the mouse Ubr3, Ubr6 and Ubr7 E3s are not N-recognins, despite the presence of a UBR domain43,274 
(Fig. 7 and Fig. 8). The S. cerevisiae Ubr2 E3, which contains a UBR domain, is also not an 
N-recognin43,275. Cognate in vivo ligands of UBR domains of non-N-recognin E3s remain to be 
identified. The identical names of mammalian Ubr2 and S. cerevisiae Ubr2 are functionally 
incongruent, in that only mammalian Ubr2 is an N-recognin. 
Studies with mice, flies and plants indicated a broad range of physiological functions of Ubr4 
and Ubr5/Edd (refs. 15,31,265-269 and refs. therein), but analyses of these E3s vis-á-vis their 
functions as N-recognins have yet to take place. Specific interactions of the type-1/2 binding sites of 
the S. cerevisiae Ubr1 N-recognin with dipeptides bearing Ndp residues were shown to allosterically 
activate a third binding site of Ubr1, thereby accelerating the degradation of its target, Cup9, in a 
circuit that ‘senses’ the presence of extracellular peptides and accelerates their uptake27,29,138 
(Fig. 15). It would be, therefore, particularly informative to determine whether the analogous 
N-degron-binding sites of, e.g., mammalian Ubr4 and Ubr5/Edd also function to regulate, 
allosterically, the activity of other substrate-binding sites of these E3s. 
A recent advance276 opened up yet another dimension in studies of the mammalian N-end rule 
pathway. As in the rest of the Ub system, the ‘upstream’ steps of polyubiquitylation of mammalian 
N-end rule substrates are mediated by the Ub-activating (E1) enzyme Uba1, which transfers the 
activated Ub moiety to cognate E2 enzymes such as Ube2A/Ube2B (the mammalian counterparts of 
the S. cerevisiae Rad6 E2). It was shown that Uba6-Use1, a different pair of E1-E2 enzymes, also 
functions in the Arg/N-end rule pathway, in that the Use1 E2 of this pair is a component of 
‘alternative’ E2-E3 Ub ligases that contain UBR-type N-recognins such as Ubr1 and Ubr2276. 
 
9.2. N-terminal deamidation in the Arg/N-end rule pathway 
In S. cerevisiae, the deamidation branch of the Arg/N-end rule pathway is mediated by the 
NTA1-encoded 52-kDa NtN,Q-amidase. Nta1 can deamidate either N-terminal Asn (N) or N-terminal 
Gln (Q), converting them into Asp or Glu, respectively, and thereby enabling the Nt-arginylation of 
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resulting proteins by the Ate1 R-transferase23 (Fig. 2A). Although there is enough of Nta1 in the 
yeast cytosol (and possibly in the nucleus as well) to mediate the deamidation branch of the 
Arg/N-end rule pathway23, the bulk of Nta1 was shown to reside in mitochondria 
(http://yeastgfp.yeastgenome.org/), in agreement with our findings (H.-R. Wang and A.V., unpubl. 
data). NTA1 apparently encodes both forms of NtN,Q-amidase, as there are two alternative start (ATG) 
codons in the NTA1 open reading frame (ORF), with a putative mitochondrial presequence between 
them23. Physiological substrates of the S. cerevisiae Nta1 NtN,Q-amidase are unknown. Apart from the 
inability of nta1∆ yeast cells (in contrast to wild-type cells) to degrade engineered cytosolic N-end 
rule substrates that bear N-terminal Asn or Gln, no defects could be detected, thus far, with nta1∆ 
cells, including the apparent absence of defects in their mitochondria (ref. 23; H.-R. Wang and A.V., 
unpubl. data). One possibility is that the mitochondrial pool of Nta1 may function in the recently 
discovered mitochondrial N-end rule pathway277,278 (Section 11). 
In contrast to S. cerevisiae, where a single NtN,Q-amidase deamidates both N-terminal Asn 
and N-terminal Gln (Fig. 2A), the deamidation branch of the Arg/N-end rule pathway is bifurcated in 
multicellular eukaryotes. Specifically, the mammalian Ntan1-encoded 35-kDa NtN-amidase 
deamidates solely N-terminal Asn, whereas the Ntaq1-encoded 24-kDa NtQ-amidase deamidates 
solely N-terminal Gln25,42,116,117 (Fig. 3). Mouse Ntan1 and Ntaq1 are present largely in the cytosol 
and the nucleus25,42, in contrast to the largely mitochondrial location of S. cerevisiae Nta1. Ntan1-/- 
mice, which lack NtN-amidase and cannot degrade N-end rule reporters bearing N-terminal Asn, are 
hypokinetic and have a significantly impaired spatial memory25. The recently constructed Ntaq1-/- 
mouse strains, which lack NtQ-amidase and cannot degrade N-end rule reporters bearing N-terminal 
Gln, also exhibit behavioral abnormalities (K. Piatkov, N. Malkina, H. Wang, C. Brower and A.V., 
unpubl. data). Given their different N-terminal residues, Asn versus Gln, the physiological substrates 
of NtN-amidase (Ntan1) and NtQ-amidase (Ntaq1) are unlikely to overlap. 
In D. melanogaster, the cleavage, by an initiator caspase, of the antiapoptotic E3 Ub ligase 
DIAP1 converts it into an N-end rule substrate (still active as a Ub ligase) that bears N-terminal Asn 
and is degraded by the deamidation branch of the Arg/N-end rule pathway140,141 (Fig. 10). 
Furthermore, an autocleavage, by the human USP1 deubiquitylase, produces a short-lived C-terminal 
fragment of USP1 that may be a physiological substrate of the Ntaq1 NtQ-amidase279. A number of 
putative (unverified) substrates of NtN-amidase and NtQ-amidase are known to be produced by 
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nonprocessive intracellular proteases, including caspases (Fig. 3, Fig. 10, Section 5, and 
refs. 156-160). 
Strong sequelogs1 of the mammalian Ntaq1 NtQ-amidase are present throughout the animal 
phylum (including fishes, insects and nematodes), in plants, and also in some fungi, such as the 
fission yeast S. pombe42. Similarly, there are strong sequelogs of the mammalian Ntan1 NtN-amidase 
in other animals, and in some fungi as well. The S. cerevisiae Nta1 NtN,Q-amidase has sequelogs in 
many but not in all fungi. For example, S. pombe contains a sequelog of mammalian Ntaq1 but lacks 
a sequelog of S. cerevisiae Nta1. Remarkably, there is no significant sequelogy (sequence similarity1) 
among Nta1, Ntan1 and Ntaq1, although all three Nt-amidases catalyze identical or similar 
reactions42. A parsimonious explanation is that a primordial Nta1 NtN,Q-amidase emerged after (not 
before) a split between lineages that gave rise to fungi and lineages that led to other eukaryotes. This 
otherwise plausible explanation is incomplete, given the presence of a sequelog of mammalian Ntaq1 
in the yeast (fungus) S. pombe and the absence, from S. pombe, of a sequelog of S. cerevisiae Nta1. 
Progress in biological research, including high-throughput structural studies, has produced a 
disposition all but improbable a decade ago: the mouse Ntaq1 NtQ-amidase, which was isolated, 
cloned and characterized in 2009, found itself surrounded by directly relevant genomic, proteomic 
and even crystallographic evidence42. The earlier data, produced through studies of a specific gene 
and its encoded 24-kDa product of unknown biochemical nature, have become unified and informed 
by the revealed enzymatic identity of Ntaq1, its mechanistic similarity to transglutaminases, and its 
place in the Arg/N-end rule pathway42 (Fig. 3 and Fig. 14). Specifically, a mutant, termed tungus, in 
the D. melanogaster Cg8253 locus, which turned out to encode NtQ-amidase42, has defective 
long-term memory280. In addition, the expression of the nematode (C. elegans) counterpart of mouse 
Ntaq1 is regulated by neuron-specific transcription factors (ref. 42 and refs. therein). These findings 
are consistent with behavioral abnormalities of Ntaq1-/- mice and a major role of the Arg/N-end rule 
pathway in mammalian brain development271.  
The rat Ntan1 gene, encoding NtN-amidase (Fig. 3), was found to be induced by ~3-fold after 
a 15-min exposure of rat hippocampal neurons to a static 100 mT magnetic field281. A transient 
overexpression of Ntan1 in these cells (in the absence of magnetic field treatment) strongly 
down-regulated, through induced proteolysis, the level of Map2, a microtubule-associated protein281. 
Map2 is also known to be down-regulated by magnetic fields281. Thus Ntan1 might be involved in 
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degradation of Map2, through an unknown processing step that would expose the Asn residue at the 
N-terminus of a cleaved Map2. 
 
9.3. N-terminal arginylation in the Arg/N-end rule pathway 
The Ate1 Arg-tRNA-protein transferase (R-transferase) catalyzes the conjugation of the 
carboxyl group of Arg to the α-amino group of a polypeptide’s N-terminal residue (Fig. 2A and 
Fig. 3). Strong sequelogs1 of the ~60 kDa S. cerevisiae Ate1 R-transferase are present in all 
eukaryotes examined, including animals and plants26,35,36,111,112,114. Both S. cerevisiae and mammalian 
genomes contain one ATE1 gene, whereas plants such as Arabidopsis thaliana contain two ATE1 
genes, which encode highly sequelogous R-transferases18,113. Mouse Ate1 pre-mRNAs are produced, 
in part, from the bidirectional DfaPAte1 promoter that contains a CpG island and also expresses, in the 
opposite direction, a gene termed Dfa (divergent from Ate1)35,282 (Fig. 9A). Dfa pre-mRNAs are 
expressed from both DfaPAte1 and nearby promoters, are differentially spliced, and result in a complex 
set of mRNAs and proteins, largely though not exclusively in the testis. At least one isoform of 
mouse Dfa was shown to function, in a reporter-based in vivo assay, as a repressor of TATA-box 
transcriptional promoters282. No functional or mechanistic connections between Dfa and 
R-transferase were detected so far, apart from the proximity of their head-to-head oriented genes282. 
In addition to the DfaPAte1 promoter, mouse Ate1 pre-mRNAs are also produced from an 
upstream promoter that partially overlaps, in anti-sense direction, with ORFs encoding Dfa 
proteins35,282. Six splicing-derived isoforms of the mouse Ate1 R-transferase have been 
identified26,35,112 (Fig. 9B-D). The alternatively spliced exons of these isoforms are pairs of 
sequelogous exons, 1A versus 1B and 7A versus 7B (Fig. 9D). Although the splicing-derived 
isoforms of R-transferase differ, in particular, in their substrate preferences, an unambiguously 
specific function of any Ate1 isoform (e.g., a distinct intracellular location or a unique in vivo 
substrate specificity) remains to be identified. 
Both the mouse and S. cerevisiae Ate1 R-transferases are inhibited by low-µM levels of 
hemin (Fe3+-heme)36. Hemin binds to at least one of two conserved Heme Regulatory Motifs (HRMs) 
in R-transferase and inhibits its enzymatic activity through a redox mechanism that involves the 
formation of a disulfide bond between the vicinal Cys71 and Cys72 residues that are conserved among 
R-transferases in examined eukaryotes (Fig. 9E, F). Remarkably, hemin also accelerates, in vivo, the 
degradation of mouse Ate1, thus acting as both a ‘stoichiometric’ and ‘catalytic’ down-regulator of 
R-transferase36. Moreover, hemin also binds, at least in vitro, to both S. cerevisiae and mouse Ubr1 
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N-recognins. Although the binding of hemin to S. cerevisiae Ubr1 does not directly occlude any of 
the substrate-binding sites of Ubr1, hemin blocks the allosteric activation of the third binding site of 
Ubr1 that recognizes an internal degron of the Cup9 transcriptional repressor36. (In the absence of 
hemin, this allosteric activation of the third binding site is caused by the occupancy of the type-1/2 
sites of Ubr1 that recognize destabilizing N-terminal residues (Fig. 15).) Thus, in addition to being a 
sensor of NO and oxygen32,33, the Arg/N-end rule pathway is also a sensor of heme (hemin) (Fig. 2A 
and Fig. 3). Several hemoproteins, including cytochrome oxidase and NO synthases, contain hemin 
(Fe3+-heme) rather than Fe2+-heme as an essential prosthetic group283. Because heme interacts with 
physiologically relevant gases such as O2, NO and carbon monoxide (CO), there may be a 
physiological connection between the NO-sensing and heme-sensing properties of the Arg/N-end rule 
pathway (Fig. 2A and Fig. 3). One function of this proteolytic circuit may be to coordinate the redox 
dynamics of heme, NO, oxygen, thiols, and other small effectors, by sensing them through 
components of the Arg/N-end rule pathway and by acting to alter their levels or spatiotemporal 
gradients, in part through conditional degradation of specific N-end rule substrates. 
The inhibition of R-transferase by hemin is a property that is conserved from fungi to 
mammals36. What selective pressures led to the retention of the heme-Ate1 connection over vast 
phylogenetic distances? Given the cardiovascular defects of Ate1-/- mouse embryos26, their low levels 
of embryonic globin and heme, high levels of heme oxygenase36, and their perturbed hematopoiesis 
(J. Sheng, R.-G. Hu and A.V., unpubl. data), the mammalian Arg/N-end rule pathway is likely to 
participate in the control of heme synthesis, transport, and/or catabolism. This might also be a role of 
Ate1-heme connections in S. cerevisiae. Physiological functions of Nt-arginylation in S. cerevisiae 
are still a terra incognita, as no defects could be detected, thus far, in ate1∆ yeast cells, apart from 
their inability to degrade N-end rule reporters with N-terminal Nds and Ndt residues. 
The Rgs4, Rgs5 and Rgs16 regulators of G proteins bear N-terminal Cys and are targeted for 
regulated degradation by the NO/O2/Ate1-dependent branch of the mammalian Arg/N-end rule 
pathway26,32,33,41 (Sections 3 and 9.4). Rgs4 is an inhibitor of tubulogenesis, a process that underlies 
the development and homeostasis of blood vessels and other tubular structures, such as those in the 
mammary gland, kidney and lung284. Rgs4 and Rgs16 block signaling by the vascular endothelial 
growth factor (VEGF), and Rgs5 regulates vessel remodeling during neovascularization284,285. As 
described above, hemin down-regulates the Arg/N-end rule pathway in vivo, both through direct 
inhibition of the Ate1 R-transferase and through the induction of its degradation, and also (possibly) 
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through effects of hemin on N-recognins36. In particular, hemin up-regulates Rgs4, Rgs5 and Rgs16, 
by inhibiting their degradation36. Thus it is likely (but remains to be verified) that the Arg/N-end rule 
pathway is a mediator of heme’s effects on tubulogenesis. The sensor-effector link between the 
Arg/N-end rule pathway and heme may be relevant not only to normal conditions but also to 
perturbations of heme homeostasis, for example upon a ‘spontaneous’ or wound-induced 
hemorrhage, or in a hemorrhage-prone setting of a growing tumor. 
Heterozygous Ate1+/- mice appear indistinguishable from their wild-type counterparts, 
whereas Ate1-/- mice, which lack R-transferase and Nt-arginylation, die around embryonic day 15 
(E15) with abnormalities that include cardiovascular defects26. To bypass the embryonic lethality of 
the nonconditional absence of Nt-arginylation, the Cre-lox-tamoxifen technique was employed to 
induce the loss of Ate1 in juvenile (~1 month old) Ate1+/- mice41. The penetrance of Ate1+/-→Ate1-/- 
conversion ranged from ~90% of cells in the brain and kidney to ~60% of cells in the liver. 
Remarkably, the postnatal ablation of Ate1 caused a rapid decrease of body weight (in comparison to 
tamoxifen-treated control mice) and resulted in early death of ~15% of Ate1-deficient mice, with 
surviving mice attaining only ~70% of normal weight41. This failure to thrive occurred despite higher 
than normal food intake by Ate1-deficient mice. These mice contained little or no visceral fat, 
exhibited an increased metabolic rate, a decreased fasting blood glucose level, and an increased 
intestinal import and retention of amino acids and/or peptides. Ate1-deficient mice were also resistant 
to diet-induced obesity, exhibited induction of the Ucp1 uncoupling protein in white adipose tissue 
(WAT), and expressed strongly reduced levels of mRNA encoding proopiomelanocortin (POMC), a 
pituitary-produced precursor of several neurohormones with systemic and brain functions. These 
functions include regulation of melanocytes, a process that is perturbed in Ate1-deficient mice41. 
Because other roles of POMC-derived neurohormones include a down-regulation of food intake, a 
strong reduction of POMC in Ate1-deficient mice is consistent with their hyperphagia41. In addition, 
Ate1-deficient mice have an enhanced startle response and are strikingly hyperkinetic. They also 
suffer from premature kyphosis, i.e., an excessive curvature of the upper back, and from frequent 
seizures41. Ate1-deficient males are infertile, owing to defects in Ate1-/- meiotic spermatocytes. 
The remarkably broad range of biological processes that are perturbed by the loss of Ate1 and 
Nt-arginylation during embryogenesis26 and postnatally41 remains to be understood in mechanistic, 
substrate-based terms. It is virtually certain that Rgs4, Rgs5 and Rgs16, a set of regulators of 
G proteins that are conditionally short-lived physiological Ate1 substrates32,33,36, play a major role in 
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many of specific phenotypes of Ate1-/- mice26,41 (Fig. 3, Fig. 10, Section 3 and Section 9.4). But other 
Nt-arginylation substrates are likely to be involved as well. 
Studies of plant R-transferases were initiated by the identification of the A. thaliana mutant 
delayed leaf senescence (dls1) as a null in the AtAte1 gene125. Recent work, utilizing A. thaliana 
mutants lacking both AtAte1 and AtAte2 R-transferases and therefore completely lacking 
Nt-arginylation, has shown that this branch of the Arg/N-end rule pathway has a number of functions 
in plants, including seed germination (in part through the removal of sensitivity to the hormone 
abscisic acid), as well as various aspects of leave and shoot development18,113,126. In particular, 
N-terminal arginylation was shown to play a role in repressing the meristem-promoting 
BREVIPEDICELLUS (BP) gene in developing leaves113. Most or all of these R-transferase functions 
require the activity of PROTEOLYSIS6 (PRT6), an E3 N-recognin Ub ligase of the plant Arg/N-end 
rule pathway that acts downstream of R-transferases113,126,273. 
Results of recent studies by the Kashina laboratory suggested that Arg might be conjugated 
(presumably by the Ate1 R-transferase) to a number of different N-terminal residues of cellular 
proteins, i.e., that the specificity of Nt-arginylation is not confined to N-terminal Asp, Glu and 
(oxidized) Cys, and is determined, instead, by currently unknown internal sequence motifs in protein 
substrates127,286. While interesting if correct, this conjecture awaits verification, because it contradicts 
extensive previous evidence about the substrate specificity of R-transferase (Fig. 2A and Fig. 3). 
A distinct kind of Arg conjugation was demonstrated to modify neurotensin, a 13-residue mammalian 
peptide that functions as a neurotransmitter and hormone. Arg is conjugated, via its α-amino group, to 
the γ-carboxyl group of an internal Glu residue of neurotensin, presumably during maturation of 
neurotensin precursors in the secretory pathway287. In the resulting ‘branched’ Arg-neurotensin 
conjugate, the orientation of the Arg moiety is opposite to that in linear, N-terminal Arg-protein 
conjugates that are produced by the Ate1 R-transferase. Given this difference in chemistry and 
‘topology’ of Arg conjugation287, and the apparent absence of Ate1 from secretory compartments, it 
is likely (but remains to be determined) that neurotensin is arginylated by an enzyme distinct from 
Ate1. 
 
9.4. Functions of the N-end rule pathway vis-á-vis their mechanisms 
Subunit selectivity of the Arg/N-end rule pathway and degradation of a cohesin subunit. 
The subunit selectivity of processive proteolysis, first discovered in the context of the Arg/N-end rule 
pathway6,13 (Fig. 11B, C), underlies most functions of the Ub system, as it makes possible 
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remodeling of protein complexes through subunit-selective degradation (Section 6 and Fig. 11A-D). 
A cleaved subunit whose C-terminal fragment bears a destabilizing N-terminal residue would be a 
potential substrate for the degradation-mediated removal of this subunit from a protein complex13,168. 
Because the Arg/N-end rule pathway can target both N-degrons and specific internal degrons 
(Fig. 2A and Fig. 3), this remodeling can involve not only a cleaved subunit that contains an 
N-degron but also a full-length subunit of a protein complex. The Arg/N-end rule pathway can 
employ, in such settings, its capacity for subunit-specific proteolysis to reset the states of relevant 
circuits without destroying an entire oligomeric complex. 
One example is the degradation of a separase-produced fragment of a cohesin subunit, a step 
that has been shown to be required for the high fidelity of chromosome cohesion/segregation6,28. 
Although the identity of a residue at the (inferred) N-terminus of a separase-produced Scc1/Rad21 
cohesin fragment varies among eukaryotes (for example, it is Arg in S. cerevisiae, Asn in S. pombe, 
Glu in mammals, and Cys in D. melanogaster)28,288, the N-terminal residue of a cohesin fragment is 
invariably destabilizing in the Arg/N-end rule pathway (Fig. 2A, C and Fig. 6). This constraint on 
evolutionary alterations of the N-terminal residue is consistent with the necessity of removing, 
through degradation, a separase-produced cohesin fragment from the rest of cohesin, thereby 
‘resetting’ the cohesin complex for reconstitution through the addition of an uncleaved Scc1/Rad21 
subunit28,288.  
The C-terminal cohesin fragment can presumably dissociate (or be displaced) from the rest of 
cohesin complexes in vivo at a rate that allows the functioning of the cohesin machinery even in the 
absence of degradation of this fragment by the Arg/N-end rule pathway. But such a route is 
apparently inefficient enough to cause a greatly elevated frequency of chromosome loss in ubr1∆ 
S. cerevisiae cells and an increased genomic instability in ate1∆ mammalian cells. The 
separase-produced C-terminal fragments of Scc1/Rad21 cohesin are relatively stable proteins in both 
of these mutants, in contrast to their short half-lives in wild-type cells6,28. It has also been shown that 
at least in yeast it is specifically the metabolic stabilization of the Scc1 cohesin fragment (as 
distinguished from other effects of the absence of the Arg/N-end rule pathway) that increases the 
frequency of chromosome loss28. Another example of subunit-selective proteolysis is a circuit that 
regulates the import of peptides through the degradation of Cup9, a transcriptional repressor of the 
peptide transporter Ptr2. The S. cerevisiae Arg/N-end rule pathway targets Cup9, through its internal 
degron, for a subunit-selective, conditional degradation. Specifically, the short-lived Cup9 is a part of 
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a repressor complex that also contains the more abundant and longer-lived Ssn6-Tup1 global 
repressor27,138 (Fig. 15). 
Regulation of G proteins and the Arg/N-end rule pathway. As mentioned in Sections 3, 5 
and 9.3, the functions of the mammalian Arg/N-end rule pathway include the sensing of NO and 
oxygen, and the regulation of specific G proteins that are coupled to transmembrane receptors. These 
processes involve the NO/O2-dependent degradation of Rgs4, Rgs5 and Rgs16, a set of G-protein 
regulators32,33,36 (Fig. 3 and Fig. 10). The conditional Nt-arginylation and degradation of these RGS 
proteins by the Arg/N-end rule pathway alters the activity of cognate G-protein circuits32,33. In 
particular, it has been shown that an induction of angiogenesis specifically in the heart results in a 
strong myocardial hypertrophy (through enlargement of cardiomyocytes), apparently because an 
increased density of the heart’s vascular bed augments the levels of NO that is produced by 
endothelial cells289. If so, this effect of increased NO on cardiomyocytes is likely to be mediated, at 
least in part, through an acceleration of the NO/O2-dependent degradation of Rgs4 (as well as Rgs5 
and Rgs16) by the Arg/N-end rule pathway in NO-exposed cardiomyocytes. Indeed, the inhibition of 
Gq-protein signaling by Rgs4 is known to be a negative modulator of the myocardial hypertrophic 
response (ref. 289 and refs. therein). In sum, the Arg/N-end rule pathway is likely to be a major 
regulator of the heart. Recent studies indicated that the rate of degradation of Rgs4, largely by the 
Arg/N-end rule pathway (Fig. 3), influences other physiological and pathophysiological processes as 
well, including the invasiveness of breast cancer, responses of neurons to opiates, and responses of 
cells in culture to fluxes of calcium ions290,291. 
The Cre recombinase-induced postnatal loss of the mouse Ate1 R-transferase and 
Nt-arginylation (Section 9.3) leads to a more than 10-fold increase in the level of the metabolically 
stabilized Rgs4 in Ate1-deficient mice, suggesting a major decrease in signaling by Rgs4-regulated 
G proteins41. Although the loss Nt-arginylation does result in a number of phenotypic alterations in 
Ate1-deficient mice (Section 9.3), it is remarkable that the strikingly strong effect of this loss on the 
levels of several RGS proteins32,41 is still compatible with most physiological functions. This 
robustness implies a compensatory feedback regulation, which remains to be explored. 
Regulation of apoptosis and the Arg/N-end rule pathway. As mentioned in Section 9.2, one 
example of involvement of the Arg/N-end rule pathway in the control of apoptosis is the conditional 
degradation of D. melanogaster DIAP1, a major antiapoptotic regulator140,141 (Fig. 10). A functional 
understanding of DIAP1 circuits vis-á-vis the Arg/N-end rule pathway remains to be attained. Some 
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C-terminal fragments of other proteins that are cleaved by activated initiator and/or effector caspases 
are either previously demonstrated or putative (predicted) N-end rule substrates (Section 5 and 
Fig. 10). Such fragments bear destabilizing N-terminal residues and would be expected to be targeted 
for degradation by the Arg/N-end rule pathway (refs. 6,140,141,146,147 and refs. therein). If the 
cleavage of a protein by, for example, an initiator caspase produces a proapoptotic C-terminal 
fragment, a destabilizing N-terminal residue and (therefore) a short in vivo half-life of such a 
fragment would counteract the induction of apoptosis by spuriously activated caspases that are 
present even in unperturbed cells, given the level of noise in caspase-activation circuits. This 
antiapoptotic role of the Arg/N-end rule pathway was recently found to be significant not only in 
relatively unstressed cells but under proapoptotic conditions as well (K. Piatkov, C. Brower and A.V., 
unpubl. data). 
Human immunodeficiency virus-1 (HIV-1) integrase and the Arg/N-end rule pathway. 
During infection by the human immunodeficiency virus (HIV), the viral RNA genome is 
reverse-transcribed, and the resulting cDNA is inserted into the chromosomal DNA of infected 
mammalian cells. This process is mediated by HIV integrase, in association with viral and host 
proteins. The integrase is a member of the family of structurally related DNA transferases that 
includes phage transposases and mammalian VDG recombinases RAG1 and RAG2. The HIV 
integrase is initially a part of the HIV Gag-Pol polyprotein that resides in the virion. The integrase is 
excised from the polyprotein by the viral protease while still in the virion, and is released into the 
cytosol upon infection. At this stage, the excised integrase bears N-terminal Phe, an Ndp residue in 
the Arg/N-end rule pathway (Fig. 3 and Fig. 10), and has been shown to be targeted by this pathway 
for degradation132,133 (t1//2 < 30 min). In contrast, the otherwise identical integrase bearing, for 
example, N-terminal Met, was significantly longer-lived in vivo132.  
Mutant HIV-1 viruses in which the N-terminal residue of (excised) integrase was changed 
from Phe to Met were viable but impaired (~5-fold or more) in replication and infectivity, in 
comparison to otherwise identical viruses containing Phe-integrase133. This impairment included 
defects in early phases of infection, particularly reverse transcription and integration of the viral 
cDNA. Control experiments have shown that the impairment was not caused by a lower efficiency of 
Met-integrase excision from the polyprotein, in comparison to the excision of Phe-integrase133. 
Specific mechanisms through which a metabolic stabilization (and thus higher steady-state levels) of 
integrase perturb both reverse transcription and integration remain to be understood. One possibility 
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is that an excess of HIV-1 integrase might inhibit reverse transcription through the known physical 
interaction between the integrase and reverse transcriptase133. The cited studies were carried out 
before the discovery of the Ac/N-end rule pathway3. Therefore, although the replacement of 
N-terminal Phe of the HIV-1 integrase with N-terminal Met stabilized the resulting protein132, it 
remains to be determined whether N-terminal Met, an Nds destabilizing residue in the Ac/N-end rule 
pathway (Fig. 2B), was Nt-acetylated in the posttranslationally formed Met-integrase (N-terminal 
sequence Met-Leu-Asp) after its release into the cytosol, and if so whether Met-integrase was 
targeted for degradation by the Ac/N-end rule pathway. 
Many viruses encode polyproteins that yield, upon excision of individual proteins by viral 
proteases, either putative or confirmed N-end rule substrates. One example (in addition to HIV-1 
integrase), is the polyprotein-derived nsP4, the RNA polymerase of the Sindbis virus. This enzyme 
has N-terminal Tyr (an Ndp residue in the Arg/N-end rule pathway) (Fig. 3) , is metabolically 
unstable, and has been shown to be partially stabilized by replacements of its N-terminal Tyr by the 
Met or Ala residues131. 
Human birth defects and the N-end rule pathway. Johanson-Blizzard syndrome (JBS) is an 
autosomal recessive disorder caused by mutational inactivation of both copies of the UBR1 gene that 
encodes an N-recognin34. JBS includes a congenital exocrine pancreatic insufficiency and 
inflammation, multiple malformations (such as nasal wing aplasia), as well as frequent mental 
retardation and deafness. The severity of JBS symptoms is decreased if at least one of the mutant 
copies of UBR1 encodes a partly functional missense hypomorph of the UBR1 E3 Ub ligase 
(C.-S. Hwang,. M. Zenker and A.V., unpubl. data). Ubr1-/- mice292 exhibit milder versions of human 
JBS symptoms, including exocrine pancreatic insufficiency34. The mechanistic cause(s) of JBS 
remains to be understood, in part because all other UBR-type N-recognins (Section 9.1), including 
UBR2, a strong sequelog of UBR1 that is expressed in exocrine pancreas as well, are retained in JBS 
patients. Their cells, therefore, still contain the Arg/N-end rule pathway (Fig. 3). It is possible that 
UBR1, despite being 47% identical to UBR230,292, has a JBS-relevant physiological substrate(s) that 
is confined to UBR1. In addition, previous work has shown that S. cerevisiae Ubr1 is an 
activity-limiting component of the yeast Arg/N-end rule pathway12. Thus it is also possible that some 
JBS phenotypes may be caused by a suboptimal overall activity of the Arg/N-end rule pathway in 
JBS patients, as distinguished from the loss of a function unique to UBR1. 
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Lyon and colleagues have recently identified the first human birth defect in the Ac/N-end rule 
pathway (Fig. 2B), an X-linked infantile lethal disorder caused by a hypomorphic missense mutation 
in NAA10 (hARD1), which encodes the catalytic subunit of the NatA Nt-acetylase (G. J. Lyon, a 
personal communication). This enzyme Nt-acetylates the N-terminal Ala, Ser, Thr, Val, Cys and Gly 
residues of nascent proteins after the cotranslational removal of their N-terminal Met by 
Met-aminopeptidases91-94,102. The early postnatal lethality of the human NAA10 syndrome is 
consistent with lethality of null NAA10 mutants in Trypanosoma brucei, C. elegans and 
D. melanogaster (refs. 293,294 and refs. therein). Given the necessity of Nt-acetylation for the 
activity of AcN-degrons3, an increased fraction of non-Nt-acetylated physiological substrates of NatA 
in human or other hypomorphic NAA10 mutants would be expected to (at least) partially stabilize 
these proteins against degradation. Detrimental effects of this stabilization (Section 8) may be one 
cause of the early postnatal lethality of the human NAA10 syndrome, despite a significant residual 
activity of the mutant NAA10 Nt-acetylase (G. J. Lyon, a personal communication). 
Regulation of bacterial virulence and the Arg/N-end rule pathway. Listeria monocytogenes 
is a gram-positive bacterial pathogen of humans and other animals. Following internalization into 
mammalian cells, bacteria are initially contained within host vacuoles but rapidly escape into the 
cytosol (where they grow and divide), largely through the perforation of the phagosomal membrane 
by the pore-forming toxin called listeriolysin O (LLO). LLO that is secreted from bacterial cells into 
the cytosol of mammalian cells bears N-terminal Lys, an Ndp residue (Fig. 3 and Fig. 10). LLO is 
indeed a short-lived N-end rule substrate in mammalian cells124. Moreover, replacement of 
N-terminal Lys of LLO with Val not only increased the in vivo half-life of LLO but also decreased 
the virulence of L. monocytogenes124. Thus the presence of strongly destabilizing residues at the 
N-termini of LLO toxins from L. monocytogenes and related bacteria124 is likely to have been 
selected, during evolution, to optimize, through down-regulation, the levels of secreted LLO in the 
cytosol of infected mammalian cells. 
Regulation of DNA repair and the Arg/N-end rule pathway. O6-methylguanine (O6meG) and 
related modifications of guanine in double-stranded DNA are lesions that can be produced by many 
alkylating agents, including N-methyl-N’-nitro-N-nitrosoguanidine (MNNG), a potent carcinogen. 
O6meG is repaired through demethylation by the O6-methylguanine-DNA alkyltransferase (AGT). 
This protein is called MGMT in mammals and Mgt1 in S. cerevisiae. AGT proteins remove methyl 
and other alkyl groups from an alkylated O6 in guanine by transferring the adduct to an active-site 
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Cys residue (ref. 40 and refs. therein). The resulting S-alkyl-Cys of AGT is not restored back to Cys, 
so repair proteins of this kind can act only once. Recent work has shown that S. cerevisiae Mgt1 
(preferentially but not exclusively its S-alkylated form) is targeted for polyubiquitylation and 
degradation by the Arg/N-end rule pathway, specifically by its double-E3 Ubr1/Rad6-Ufd4/Ubc4 
targeting complex40,44 (Fig. 2A and Section 9.1). The Ubr1/Ufd4-dependent Arg/N-end rule pathway 
mediates not only the constitutive but also MNNG-accelerated degradation of Mgt1. Although the 
degradation signal of Mgt1 is near its N-terminus, it is not an N-degron40,44. 
Because the Ubr1 and Ufd4 E3s physically interact, it is remarkable that the degron of Mgt1 
can be recognized, independently, by either Ubr1 or Ufd4, possibly in a mutually exclusive manner, a 
previously undescribed mode of ‘alternative’ degron recognition that remains to be understood both 
functionally and mechanistically (ref. 40; A. Shemorry, C.-S. Hwang and A.V., unpubl. data). It is 
also unknown whether the targeting and polyubiquitylation of Mgt1 by the Ubr1/Rad6-Ufd4/Ubc4 
complex can involve, in vivo, the DNA-bound Mgt1protein or whether this targeting requires a 
dissociation of Mgt1 from DNA. A priori, it is likely (nothing is known about this at present) that 
Mgt1 functions as a part of a chromosome-associated protein complex. If so, degradation of Mgt1 
may involve the subunit selectivity of the Arg/N-end rule pathway13, an aspect of its activity that is 
also essential for selective degradation of the separase-produced C-terminal fragment of the Scc1 
cohesin subunit that is bound to the rest of cohesin complex28. In both cases, the alkylated 
(i.e., irreversibly inactivated) Mgt1 and the fragment of cohesin subunit are obligatory ‘dead-end’ 
products of their respective circuits that are still parts of larger complexes. As discussed above in the 
context of cohesin, the Arg/N-end rule pathway operates, in these settings, as a homeostatic device 
that employs its capacity for subunit-selective proteolysis to reset the states of relevant circuits. It is 
likely (but remains to be determined) that MGMT, the mammalian counterpart of yeast Mgt1, is also 
regulated through degradation by the Arg/N-end rule pathway. The activity of MGMT in repairing 
alkylated DNA is of major relevance to the efficacy of DNA-alkylating anticancer drugs, a set of 
cytotoxic compounds extensively employed in cancer therapy255. 
Regulation of peptide transport and the Arg/N-end rule pathway. Peptides can serve as a 
source of amino acids and nitrogen in all organisms. The import of di- and tripeptides (di/tripeptides) 
in S. cerevisiae is controlled by the Arg/N-end rule pathway295,296 through a specific design of the 
Ubr1 E3 Ub ligase. The type-1/2 substrate-binding sites of Ubr1 bind to the type-1 and type-2 
destabilizing N-terminal (Ndp) residues of proteins or short peptides, whereas the third binding site of 
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Ubr1 recognizes an internal degron of Cup9, a homeodomain transcriptional regulator, largely a 
repressor, of more than 30 genes38,138. The regulon of Cup9 includes PTR2, a gene encoding the main 
importer of di/tripeptides297,298. The binding of imported di/tripeptides bearing destabilizing 
N-terminal residues to the type-1/2 sites of Ubr1 allosterically activates the otherwise autoinhibited 
Cup9-binding site of Ubr1. The resulting increase in the fraction of Ubr1 molecules that can target 
Cup9 for polyubiquitylation leads to a faster degradation of Cup9 (t1/2 < 2 min) and thereby causes a 
derepression of the PTR2 gene. This positive-feedback circuit allows S. cerevisiae to detect the 
presence of extracellular peptides and to react by increasing the rate of their uptake27,29,138 (Fig. 15). 
Genes of the Cup9 regulon other than PTR2 that are also induced by di/tripeptides include additional 
components of the peptide transport and utilization system, for example OPT2, which encodes an 
oligopeptide importer, and also peptidases that process imported peptides to amino acids297,299.  
The properties of S. cerevisiae Ubr1 that underlie the regulation of peptide import through the 
conditional degradation of Cup9 were found to require phosphorylation of Ubr1 at Ser300 by the 
sequelogous type-I caseine kinases Yck1 and Yck2 (Fig. 7A, B and Fig. 15). Interestingly, the 
phosphorylation of Ubr1 at Ser-300 by Yck1/2 initiates (‘primes’) a specific phosphorylation cascade 
that results in phosphorylation of Ser296, Ser292, Thr288, and Tyr277 of Ubr1 by Mck1, a kinase of the 
glycogen synthase 3 (Gsk3) family39 (Fig. 7A, B). In contrast to the functionally critical 
phosphorylation at Ser300 by Yck1/2, the subsequent phosphorylations of Ubr1 by the Mck1 kinase 
had at most minor effects on the known properties of Ubr1, including regulation of peptide import39. 
A function of Ubr1 that requires the Mck1-mediated phosphorylation cascade (Fig. 7A, B) remains to 
be discovered. 
The induction of the Ptr2 transporter by di/tripeptides, a process controlled by the Arg/N-end 
rule pathway (Fig. 15), is just one of regulatory inputs that couple Ptr2 expression to the availability 
and quality of nutrients. For example, Ptr2 expression is down-regulated by certain nitrogen sources, 
including ammonia, but not by other nitrogen sources, such as urea or allantoin300. Several systems, 
including the Arg/N-end rule pathway, ensure that a cell does not waste resources synthesizing large 
amounts of the Ptr2 transporter in the absence of extracellular peptides, or when a more efficacious 
nitrogen source, such as ammonia, is present. Ptr2 is induced not only by short peptides but also by 
extracellular amino acids, particularly Leu and Trp. This response would be adaptive in natural 
habitats, because amino acids that S. cerevisiae (a scavenging heterotroph) encounters outside a 
laboratory tend to be products of protein breakdown and thus signify a likely presence of short 
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peptides. It has also not been precluded that Ptr2 might import some amino acids, in addition to 
peptides. 
Extracellular amino acids regulate S. cerevisiae Ptr2 through the SPS (SSY1-PTR3-SSY5) 
system301-304. Ssy1 is an integral membrane protein and sensor of amino acids that does not function 
as a transporter. Ssy1 ‘measures’ the concentration ratio of an amino acid across the plasma 
membrane and signals through the rest of the SPS pathway to induce a regulon that includes a 
number of amino acid transporters as well as the Ptr2 peptide transporter. This signaling employs a 
proteolytic activation of latent (conditionally cytosolic) transcriptional activators Stp1 and Stp2, 
leading to their import into the nucleus and the induction of the SPS regulon301-304. Our recent work 
has shown that an extracellular amino acid such as Trp acts via the SPS system to induce the 
Ptr2-mediated import of di/tripeptides not only through activation of positive transcriptional 
regulators such as Stp1/2 but also through acceleration of the degradation of the Cup9 repressor by 
the Arg/N-end rule pathway138 (Fig. 15). 
It is likely that the Arg/N-end rule pathway regulates peptide transport in multicellular 
eukaryotes as well. In contrast to S. cerevisiae, mammalian cells contain peptide transporters not only 
in the plasma membrane but also in the ER membrane. These ER proteins, called TAP transporters, 
mediate the import of peptides (including peptides produced by the proteasome-mediated degradation 
of cytosolic and nuclear proteins) from the cytosol into the lumen of ER, where these peptides are 
loaded onto MHC class I proteins en route to the cell surface, for presentation of MHC-peptide 
complexes to T lymphocytes305. Might a mammalian peptide-sensing circuit based on the Arg/N-end 
rule pathway regulate the expression of TAP transporters as well? This and related questions remain 
to be addressed.  
Results of a recent study suggested that the mammalian Arg/N-end rule pathway plays a role, 
through the Ubr1 and Ubr2 N-recognins, in the control of protein synthesis by amino acids306. 
Specifically, mammalian Ubr1 and Ubr2 appear to recognize (bind to) free Leu (ref. 306), as 
distinguished from the binding of these N-recognins to dipeptides bearing N-terminal Leu. Such 
dipeptides bind to, in particular, S. cerevisiae Ubr1 with Kd in a low-µM range38 (Section 9.1). In 
contrast, S. cerevisiae Ubr1 has a considerably (more than 10-fold) lower affinity for free amino 
acids38. Therefore it remains to be determined, using quantitative binding assays that involve free 
(non-immobilized) Leu, whether its affinity for mammalian Ubr1 is in a range that would be likely to 
be relevant physiologically. The possibility of Ubr1/2 involvement in the control of protein synthesis 
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was also suggested by the finding that overexpression of rat Ubr1 and Ubr2 in rat cells inhibited the 
activity of mTOR kinase, a key regulator of translation, and that the inhibition could be reversed by 
millimolar levels of Leu in the medium306. 
The N-end rule pathway and degradation of misfolded proteins. Errors in specific steps of 
protein synthesis result, conservatively, in 5% to 20% of molecules of a 50 kDa protein containing at 
least one missense alteration that is not encoded by DNA307,308. Premature termination of translation 
and frameshifts are additional sources of defective polypeptides. The misfolding and aggregation of 
mistranslated proteins and the resulting toxicity are significant even in the absence of environmental 
insults307-311. Recent studies have shown that Ubr1, the E3 N-recognin of the S. cerevisiae Arg/N-end 
rule pathway, is a part of quality-control systems that function to selectively eliminate misfolded 
proteins in the nuclear and cytosolic compartments119-121. In yeast, these systems include the import 
(assisted by chaperones of the Hsp70 family) of misfolded cytosolic proteins into the nucleus, 
followed by their degradation there by pathways that involve both the San1 E3 Ub ligase and the 
Ubr1-mediated Arg/N-end rule pathway120,121,312-314. UBR-type N-recognins of the mammalian 
Arg/N-end rule pathway were also found to play a role in degradation of misfolded proteins122. 
Does the S. cerevisiae Ubr1 N-recognin mediate the degradation of misfolded proteins as the 
double-E3 Ubr1-Ufd4 complex (Fig. 2A), or does it, perhaps, interact with other, ‘alternative’ E3s as 
well? Does the targeting of misfolded proteins by Ubr1 involve N-degrons that would be produced 
through preliminary cleavages of misfolded proteins by (nonprocessive) proteases, or are such 
proteins targeted by the Arg/N-end rule pathway through their internal degrons, exposed as a result of 
misfolding? If so, are these degrons recognized by the substrate-binding sites of Ubr1 that target the 
internal degrons of the Cup9 repressor29,38 or the Mgt1 DNA repair protein40, or does the targeting of 
misfolded proteins involve other, currently unknown binding sites of Ubr1? Does the in vivo 
degradation of some misfolded proteins also involve the Ac/N-end rule pathway and AcN-degrons3 
(Fig. 2B)? These cotranslationally formed N-degrons are present in a majority of cellular proteins, 
and were suggested to mediate the selective elimination of unassembled, misfolded or otherwise 
aberrant proteins3 (Section 8). If AcN-degrons contribute to selective destruction of misfolded 
proteins, might some of the E3s involved that are presumed, at present, to function outside of the 
Ac/N-end rule pathway, have binding sites for AcN-degrons? As illustrated by these questions, our 
understanding of the Arg/N-end rule and Ac/N-end rule pathways as components of protein quality 
control is just beginning. 
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The roles of the N-end rule pathway described above are but a small subset of its currently 
known functions, summarized in Section 3. Many of these functions were discovered through genetic 
approaches and therefore remain to be understood in mechanistic, substrate-based terms. 
 
10. Prokaryotic N-end rule pathways 
Although prokaryotes (bacteria and archaea) lack a bona fide Ub system, at least 
gram-negative bacteria contain a Ub-independent version of the N-end rule pathway, termed the 
Leu/N-end rule pathway (Sections 3 and 5, Fig. 5 and Fig. 6). The Leu/N-end rule pathway was 
discovered in 1991 (ref. 14), and was characterized in gram-negative bacteria E. coli and Vibrio 
vulnificus16,37. It comprises the following components14,16,19,37,71-79,81,186,188,189,191,199,315-318. (1) ClpAP, 
a proteasome-like, ATP-dependent protease; (2) ClpS, the 12-kDa N-recognin of the Leu/N-end rule 
pathway that binds to N-terminal Leu, Phe, Trp or Tyr (the pathway’s Ndp residues) and delivers 
N-end rule substrates to the ClpAP protease (Fig. 5 and Fig. 6B-D); (3) Aat, an L/F-transferase that 
employs Leu-tRNA or Phe-tRNA as a cosubstrate to conjugate largely Leu (and occasionally Phe) to 
the N-termini of proteins bearing N-terminal Lys or Arg, the secondary destabilizing (Nds) residues 
of the Leu/N-end rule pathway (in contrast, Lys and Arg are Ndp residues in eukaryotes; Fig. 2A; cf. 
Fig. 5). Crystal structures of Aat suggested a catalytic mechanism of this enzyme316-318; (4) Bpt, an 
L-transferase that employs Leu-tRNA to conjugate Leu to N-terminal Asp, Glu, and (possibly) 
oxidized Cys (Fig. 5B). 
V. vulnificus contains both the Aat and Bpt L-transferases, but E. coli contains only Aat. 
Therefore N-terminal Arg, Lys, Asp and Glu are secondary destabilizing (Nds) residues in 
V. vulnificus, whereas in E. coli the N-terminal Asp and Glu are stabilizing (‘non-destabilizing’) 
residues37 (Fig. 5). In V. vulnificus, the two L-transferases are encoded by the aat-bpt operon, but in 
several other gram-negative bacteria these genes are unlinked, and some gram-negatives lack one or 
the other of these L-transferases (for example, E. coli lacks Bpt)37. Genomes of examined 
gram-negative bacteria encode ClpS, but archaea (archaebacteria) and gram-positive bacteria appear 
to lack significant sequelogs of Aat, Bpt, and ClpS, and thus may lack the Leu/N-end rule pathway. 
This is a tentative conclusion, because, to the best of my knowledge, no biochemical tests, using 
N-end rule reporter proteins, for the presence of a Leu/N-end rule pathway or its analog have been 
carried out, thus far, with a gram-positive bacterium or an archaeon.  
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The ~27-kDa bacterial Bpt L-tranferases are sequelogous to the ~60-kDa eukaryotic Ate1 
R-transferases (Figs. 6A), strongly suggesting their homology, i.e., a common ancestry in evolution. 
In contrast to Ate1 R-transferases, Bpt L-transferases contain the CP....CXXCXXC motif (Fig. 6A; 
X is any residue; in some Bpt enzymes, Pro is replaced by Ser or other residues). This set of 
sequences is one of consensus motifs for binding a complex of nonheme iron and inorganic sulfide 
called a Fe-S cluster. Such complexes are present in many proteins and mediate a broad range of 
biological processes, including respiration, photosynthesis, redox catalysis, gene regulation, and a 
variety of enzymatic reactions319,320. At least some cysteines of the CP....CXXCXXC motif are 
required for the activity of the V. vulnificus Bpt L-transferase. The presence of this motif (Fig. 6A) 
and spectroscopic properties of isolated Bpt are consistent with it being a Fe-S cluster protein 
(H. Wang and A. V., unpubl. data). 
Specific mechanisms of the ClpS/ClpAP-mediated targeting and degradation of N-end rule 
substrates by the bacterial Leu/N-end rule pathway16,75,76,78,82 are described in Section 5 (Fig. 12). 
These mechanisms are understood in greater detail than the analogous but Ub-dependent targeting in 
the eukaryotic Arg/N-end rule pathway (Section 5, Fig. 2A, Fig. 3 and Fig. 11). A sequelogy 
(sequence similarity) between the substrate-binding segment of the 12-kD bacterial ClpS N-recognin 
and the functionally analogous segment of a vastly larger E3 Ub ligase such as the yeast or 
mammalian Ubr1 N-recognin (Fig. 6D) suggests homology, i.e., a common descent of bacterial and 
eukaryotic N-recognins (Section 12). 
Two physiological substrates of the Leu/N-end rule pathway have recently been 
discovered76,77. One of them is Dps, an 18-kDa DNA-binding protein that compacts the nucleoid of 
E. coli in starving cells, forming highly ordered, crystal-like structures. An unknown protease 
removes 5 residues from the initial N-terminus of Dps, producing N-terminal Leu (an Ndp residue) 
and thereby making Dps a short-lived N-end rule substrate. In a plausible model, a protease that 
produces the N-degron of Dps may do so in a regulated manner, at a time when the bulk of Dps 
should be removed from DNA through processive degradation by the Leu/N-end rule pathway. 
Remarkably, Dps can also be destroyed as the full-length (uncleaved) protein, by another processive 
protease, ClpXP, which targets the N-terminus-proximal segment of Dps. This segment is at least 
partially removed by a protease that produces the N-degron of Dps. An interplay between 
ClpS-dependent and ClpS-independent degradation of Dps, and physiological ramifications of this 
circuit remain to be understood76,77.  
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The other identified N-end rule substrate is the E. coli YgjG putrescine-aminotransferase 
(PATase). It is targeted for degradation by the Leu/N-end rule pathway through a route that requires 
Nt-leucylation by the Aat L/F-transferase76,77 (Fig. 5A). The evidence by Ninnis et al.77 suggests that 
Aat can conjugate Leu or Phe to the (initially present) N-terminal Met residue of PATase, as 
distinguished from the previously characterized specificity of Aat, which conjugates (preferentially) 
Leu to N-terminal Arg or Lys of N-end rule substrates. It is possible that the active site of the Aat 
L/F-transferase might be able to accommodate the N-terminal Met of a substrate for its conjugation to 
Leu if the substrate’s second residue is, for example, Asn, a small hydrophilic residue77. It remains to 
be determined whether Aat can Nt-leucylate, in vivo, some N-terminal motifs that contain N-terminal 
Met. Physiological roles of the degradation of the putrescine-catabolizing PATase by the Leu/N-end 
rule pathway, e.g., in controlling PATase levels as a function of in vivo putrescine levels76,77, remain 
to be addressed as well. 
Both gram-negative and gram-positive bacteria employ the Nt-formylated Met residue (fMet) 
to initiate the synthesis of a polypeptide chain. The resulting N-terminal fMet of nascent bacterial 
proteins is cotranslationally deformylated by a ribosome-bound deformylase321. In contrast to bacteria 
and similarly to eukaryotes, archae initiate translation using unmodified Met, and in addition 
cotranslationally Nt-acetylate a large subset of their proteins322. The protein α1 is one of two subunits 
that form the 20S core proteasome in the archaeal prokaryote Haloferax volcanii. Interestingly, the 
in vivo concentration of α1 was found to depend on the identity of a second-position residue that 
follows the N-terminal Met of the α1 protein323. In particular, the levels of N-terminal mutants of the 
α1 subunit that were partially non-Nt-acetylated were strikingly higher than the levels of 
Nt-acetylated (wild-type) α1, in the absence of increased expression of α1 mRNA323. Although the 
authors did not consider the possibility of AcN-degrons, their findings with H. volcanii α1 and its 
mutants may be accounted for by the presence of the Ac/N-end rule pathway in archaeal prokaryotes. 
This possibility remains to be examined. 
 
11. Mitochondrial N-end rule pathway 
Mitochondria of eukaryotic cells are descendants of gram-negative bacteria, which contain the 
Leu/N-end rule pathway (Fig. 3B, C and Section 9). Might the inner matrix of mitochondria (a 
counterpart of bacterial cytosol) also contain an N-end rule pathway?5 Recent results by Pfanner, 
Meisinger, Vögtle and their colleagues did reveal such a pathway277,278,324. Specifically, most 
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N-terminal presequences of nuclear-encoded inner-matrix mitochondrial proteins are cleaved off by 
the mitochondrial processing protease (MPP) upon the import of these proteins from the cytosol into 
the matrix. The cleavage specificity of mitochondrial MPP (it is similar to that of the signal peptidase 
in the ER membrane) often results in N-terminal residues of processed proteins that are destabilizing 
in both the bacterial Leu/N-end rule pathway and the eukaryotic (cytosolic/nuclear) Arg/N-end rule 
pathway (Fig. 2A, Fig. 4B and Fig. 5). Vögtle et al.277 identified an aminopeptidase, termed Icp55, in 
the mitochondrial matrix of S. cerevisiae that removes a single (bulky hydrophobic) destabilizing 
residue from the N-termini of matrix-imported, MPP-processed mitochondrial proteins. This 
processing step tends to yield proteins that bear unmodified N-terminal residues such as Ala, Ser or 
Thr. Remarkably, some of the normally long-lived mitochondrial-matrix proteins become short-lived 
in icp55∆ cells, whose mitochondria lack the Icp55 protease277.  
Thus at least the bulky hydrophobic N-terminal residues, which are destabilizing in both the 
Arg/N-end rule pathway and the bacterial Leu/N-end rule pathway (Fig. 4B), are destabilizing in 
mitochondria as well, except that in wild-type cells these residues are cleaved off, by Icp55, from the 
N-termini of imported matrix proteins. One function of the Icp55 aminopeptidase is apparently to 
reduce or preclude the degradation of newly imported mitochondrial proteins by an N-end rule 
pathway in this organelle277,278. Yet another mitochondrial processing peptidase, Oct1, also 
contributes, in addition to Icp55, to modifying the N-termini of specific proteins that are imported 
into the matrix, so that their mature N-terminal residues are not destabilizing in the bacterial-type 
N-end rule324. In oct1∆ yeast cells, the substrates of the Oct1 protease retain destabilizing N-terminal 
residues (Fig. 4B and Fig. 5) and are short-lived in the inner matrix324.  
Mitochondria presumably ‘inherited’ their N-end rule pathway from their bacterial ancestors. 
It is likely that processing proteases such as Icp55 and Oct1 evolved as ‘suppressors’ that prevent the 
degradation of otherwise short-lived mitochondrial N-end rule substrates that form upon the import of 
proteins from the cytosol into the matrix. If so, what exactly is the function of the N-end rule pathway 
in mitochondria? In particular, what mitochondrial proteins remain physiological N-end rule 
substrates in the presence of Icp55 and Oct1, which ‘rescue’ specific proteins from becoming 
substrates of the N-end rule pathway? What is the identity of an N-recognin and a processive 
‘downstream’ protease that recognize and degrade N-end rule substrates in mitochondria? These 
questions remain to be addressed. Because yeast Icp55 and Oct1 are evolutionarily conserved 
proteases, an N-end rule pathway is likely to be present in mitochondria of all eukaryotes. 
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Remarkably, putative counterparts of mitochondrial Icp55 are also present at least in the cytosol277. 
Thus a previously unexplored possibility is that some cytosolic/nuclear substrates of the Arg/N-end 
rule pathway may be subject to N-terminal ‘editing’ (and thus a rescue from degradation) by specific 
aminopeptidases that would act, in such settings, similarly to the mitochondrial Icp55 and Oct1 
proteases. 
Chloroplasts of plant cells are descendants of ancient cyanobacteria, which may have also 
contained an N-end rule pathway. Indeed, chloroplasts (but apparently not mitochondria) contain a 
strong sequelog of bacterial ClpS N-recognins (Fig. 6D), suggesting a chloroplast Leu/N-end rule 
pathway. This possibility remains to be verified. 
 
12. Evolution of the N-end rule pathway 
An N-terminal residue is present even in dipeptides. Thus N-degrons of polypeptide substrates 
were available as targets of proteolytic systems from early stages of protein evolution, in agreement 
with the presence of N-end rule pathways in both prokaryotes and eukaryotes. Primordial 
polypeptides, produced by ribozymes that eventually became ribosomes325,326, were at first (most 
likely) short, disordered and therefore prone to aggregation or other noncognate interactions. Thus 
damage control pathways that involve chaperones and selective proteolysis182,327 were probably as 
vital at the dawn of protein-based life as they are in extant cells. Prior to emergence of quasi-modern 
proteins, primordial proteases and chaperones consisted, at least in part, of specific RNAs or other 
nucleic acids. Over ensuing eons, a succession of changes, driven by selection for cells that produced 
optimal amounts of fitness-increasing polypeptides, led to the emergence of the genetic code, 
ribosomes and the rest of the translation apparatus. This evolution also led to DNA-encoded 
polypeptides that began to resemble their modern counterparts, including functional properties of 
specific proteins and their ability to stay in solution. Fundamental similarities among the extant 
bacteria, archaea and eukaryotes indicate that the last universal common ancestor (LUCA) of modern 
organisms was a cell that expressed a broad range of proteins326,328-330. LUCA also contained 
proteolytic systems, including, probably (for the reasons above), an N-end rule pathway. 
The Nt-acetylation of cellular proteins apparently predated LUCA, as both bacteria, archaea 
and eukaryotes contain Nt-acetylases91,92. Thus a version of the Ac/N-end rule pathway3 (Fig. 2B) 
may have already been in place by the time of LUCA. As to the Leu/N-end rule and Arg/N-end rule 
pathways, their presence in Gram-negative bacteria and in eukaryotes, respectively (Fig. 2A and 
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Fig. 5), suggests an emergence of a version of the Leu/N-end rule pathway in pre-LUCA cells. The 
N-terminal Leu, Phe, Tyr and Trp residues of N-end rule substrates are recognized both by the 
12-kDa E. coli ClpS and by the type-2 binding site of eukaryotic N-recognins such as the 200 kDa 
human UBR1 E3 Ub ligase (Fig. 6B-D). The highly sequelogous segments in the substrate-binding 
sites of bacterial ClpS and eukaryotic Ubr1 suggests a common ancestry for these otherwise 
nonsequelogous proteins of vastly different sizes72,74,83-85,331 (Fig. 6D), presumably through the 
emergence, at first, of a ClpS-like protein in a lineage of cells that led to LUCA. 
LUCA might have also contained early versions of Bpt and/or Aat L-transferases, which act 
upstream of ClpS in the Leu/N-end rule pathway (Fig. 5). After separation of prokaryotic and 
eukaryotic lineages, the expanding rule books of the N-end rule continued to be similar in all 
organisms (Fig. 4B), but the underlying machinery began to diverge. In particular, Ub ligases and 
deubiquitylases have emerged (or, alternatively, were retained) only in eukaryotes37,332. Some bacteria 
express mediators or inhibitors of the Ub system that are injected into eukaryotic hosts during 
infection, but these proteins do not seem to have Ub-related functions in bacteria themselves333-337. 
(Possible causes of the absence of a bona fide Ub system in extant prokaryotes are considered in 
Section 5.) In addition, the problem of recognizing basic and acidic (as distinguished from bulky 
hydrophobic) N-terminal residues in later versions of the N-end rule pathway was solved quite 
differently in eukaryotes versus bacteria. For example, the largest known bacterial N-end rule, in the 
Gram-negative bacterium Vibrio vulnificus, is similar to the N-end rule of the eukaryotic Arg/N-end 
rule pathway37 (Fig. 2A, Fig. 4B and Fig. 5). Remarkably, however, this similarity results from 
different mechanisms in bacteria versus eukaryotes: the N-terminal Arg and Lys are Ndp (primary 
destabilizing) residues in the eukaryotic Arg/N-end rule pathway, in that these basic residues (and 
N-terminal His as well) are recognized directly by the UBR domains (type-1 binding sites) of E3 
N-recognins such as Ubr1 (Fig. 2A, Fig. 3, C, Fig. 5 and Fig. 8A, B)83-85. In contrast, the N-terminal 
Arg and Lys are Nds (secondary destabilizing) residues in both E. coli and V. vulnificus, owing to the 
presence of the Aat L/F-transferase. This enzyme, which conjugates Leu (and occasionally Phe) to the 
N-terminal Arg or Lys residues14,71,316-318 (Fig. 5), is absent from examined eukaryotes. The 
Nt-leucylating bacterial Bpt L-transferases are sequelogous1 to Nt-arginylating Ate1 R-transferases of 
eukaryotes (Fig. 6A and ref. 37). Strikingly, however, bacterial Bpt L-transferases are largely 
nonsequelogous to bacterial Aat L/F-transferases37, despite the similarity of reactions catalyzed by 
Bpt and Aat (Fig. 5). 
Page 54 of 98
John Wiley & Sons
Protein Science
55 
 
One difference between bacterial and eukaryotic N-end rule pathways is particularly 
remarkable in its consistency (no exceptions so far) and the absence of a robust explanation for its 
emergence on either functional or mechanistic grounds. Specifically, the bacterial Leu/N-end rule 
pathway employs Nt-leucylation of N-end rule substrates, whereas the otherwise similar eukaryotic 
Arg/N-end rule pathway employs Nt-arginylation (Fig. 2A, Fig. 3 and Fig. 5). The 
leucylation/arginylation dichotomy exists despite a significant sequelogy1 (sequence similarity) 
between the Nt-leucylating Bpt transferases of bacteria and the Nt-arginylating Ate1 R-transferases of 
eukaryotes (Fig. 6A and ref. 37). This sequelogy suggests homology, i.e., a common ancestry of Bpt 
and Ate1. Nevertheless, the Nt-arginylating and Nt-leucylating transferases are cleanly divided, in 
extant organisms, between Bpt L-transferases in bacteria and Ate1 R-transferases in eukaryotes. This 
dichotomy is even more remarkable than described above. Specifically, Plasmodium falciparum, an 
obligatory intracellular parasite and the cause of malaria in humans, is a eukaryote that contains a 
Plasmodium-specific R-transferase37. However, this R-transferase, which is also present in other 
apicomplexans (a group of obligately parasitic unicellular eukaryotes that includes Plasmodium) but 
not in other examined eukaryotes, is a sequelog not of the bacterial Bpt L-transferase but of the 
bacterial Aat L/F-transferase37. (This would not be expected a priori, given the sequelogy between 
bacterial Bpt and non-Plasmodium eukaryotic Ate1 R-transferases.) 
Thus, irrespective of whether an Nt-arginylating R-transferase of a eukaryotic cell descended 
from a Bpt-type L-transferase or from a largely nonsequelogous Aat-type L/F-transferase (Fig. 5), the 
final result was, in all cases, the change of enzymatic specificity from that of L-transferase 
(Nt-leucylation) to that of R-transferase (Nt-arginylation). Why? There is no clear answer (to the best 
of my knowledge), in part because the replacement of Nt-leucylation in bacteria with Nt-arginylation 
in eukaryotes does not appear to have been necessary for ‘mechanistic’ reasons. Specifically, most 
UBR-type N-recognins in the Arg/N-end rule pathway of eukaryotes contain a type-2 
substrate-binding site whose ability to recognize the N-terminal Leu, Phe, Tyr Trp or Ile residues of 
N-end rule substrates is essentially identical to the recognition specificity of ClpS, the bacterial 
N-recognin (Fig. 5, Fig. 6B-D and Fig. 7A). Thus the presumably ancestral Nt-leucylation should 
have sufficed in eukaryotes, without a change to Nt-arginylation. However, Nt-arginylation did 
emerge in eukaryotes and replaced Nt-leucylation both completely and early in eukaryotic evolution. 
Specifically, the S. cerevisiae and human Ate1 R-transferases are highly sequelogous enzymes. In 
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addition, there is no Nt-leucylation in examined eukaryotes and there is no Nt-arginylation in 
examined prokaryotes. 
For reasons suggested by Lynch210 (Section 6), many aspects of molecular circuits in 
eukaryotic cells evolved through a genetic drift and occasional fixation of mildly deleterious 
mutations, as distinguished from adaptive Darwinian evolution based on positive selection. Although 
an initially nonadaptive evolution may be relevant to the emergence of Nt-arginylation in eukaryotes, 
it is most likely that a specific selection pressure favored, in primordial eukaryotes, a replacement of 
the (apparently) preceding Nt-leucylation by Nt-arginylation. What might be a reason for such a 
pressure? Discussions of LUCA and early evolution suffer from the problem that a less parsimonious, 
more convoluted scenario would be unlikely a priori (because of Occam’s razor) but cannot be 
formally precluded. With this caveat, one difference between Arg and Leu that may have caused the 
ascendancy of Nt-arginylation in eukaryotes is high reactivity of the side chain of Arg, in comparison 
to Leu, and a multitude of metabolic transitions that involve Arg, often in the context of the 
Arg/N-end rule pathway. For example, Arg is a substrate of NO synthases and the immediate 
precursor of NO. Furthermore, NO is required for the in vivo oxidation of N-terminal Cys, a 
modification that allows Nt-arginylation of the resulting Cys-sulfinate or Cys-sulfonate by the Ate1 
R-transferase of the Arg/N-end rule pathway32 (Fig. 3). Arg-tRNA is a cosubstrate of R-transferase 
and at the same time the source of Arg in proteins produced by the ribosomes, suggesting a 
competition between these uses of Arg. (But an analogous competition also exists for the 
consumption of Leu-tRNA by L-transferases versus bacterial ribosomes.) Some Arg residues in 
proteins undergo enzymatic methylation or deimination, the latter a conversion of the positively 
charged Arg to the uncharged citrulline residue338,339. 
Might the in vivo methylation or deimination of Arg in cellular proteins involve the 
N-terminal Arg residue as well? Might there be a regulatory connection, through Arg-tRNA and 
R-transferase, between the Arg/N-end rule pathway and translation by ribosomes? (Interestingly, the 
mouse Ate1 R-transferase binds to specific mRNAs and is associated with translationally active 
polysomes (R.-G. Hu, H. Wang and A.V., unpubl. data; see also ref. 114.) These are some among a 
multitude of questions that can be asked about the Arg/N-end rule pathway. The answers at hand 
have revealed a strikingly multifunctional, universally present and extensively regulated proteolytic 
circuit (Fig. 2A and Fig. 3). Explorations of bacterial and mitochondrial N-end rule pathways 
(Sections 10 and 11) continue as well. The recent discovery of the Ac/N-end rule pathway (Fig. 2B 
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and Fig. 4A) further expanded the already broad functional scope of the eukaryotic N-end rule 
pathway, and has also revealed the main physiological functions of Nt-acetylases and 
Met-aminopeptidases3 (Sections 3 and 8). Many years after the initial discovery of the N-end rule4, 
this ancient system continues to be a fount of biological insights. 
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Figure Legends 
 
Figure 1. The ubiquitin-proteasome system, the ubiquitin fusion technique, and N-terminal 
processing of newly formed proteins. A: The ubiquitin-proteasome system (Ub system)6,45-65. The 
conjugation of Ub to other proteins involves a preliminary ATP-dependent step in which the last 
residue of Ub (Gly76) is joined, via a thioester bond, to a Cys residue of the E1 (Ub-activating) 
enzyme. The ‘activated’ Ub moiety is transferred to a Cys residue in one of several Ub-conjugating 
(E2) enzymes, and from there, through an isopeptide bond, to a Lys residue of an ultimate acceptor, 
denoted as ‘protein’. E2 enzymes function as subunits of E2-E3 Ub ligase complexes that can 
produce substrate-linked poly-Ub chains. Such chains have specific Ub-Ub topologies, depending on 
the identity of a Lys residue of Ub (which contains several lysines) that forms an isopeptide bond 
with C-terminal Gly76 of the adjacent Ub moiety in a chain. Specific poly-Ub chains can confer either 
the degradation of a substrate by the 26S proteasome or other metabolic fates. Monoubiquitylation of 
some protein substrates can also occur, and has specific functions. One role of E3 is the initial 
recognition of a substrate’s degradation signal (degron). Individual mammalian genomes encode at 
least a 1,000 distinct E3 Ub ligases. B: The Ub fusion technique4,213. In eukaryotes, linear fusions of 
Ub to other proteins are cotranslationally cleaved by deubiquitylases at the last residue of Ub, making 
it possible to produce, in vivo, different residues at the N-termini of otherwise identical proteins. 
C: N-terminal processing of nascent proteins by Nα-terminal acetylases (Nt-acetylases) and 
Met-aminopeptidases (MetAPs). ‘Ac’ denotes the Nα-terminal acetyl moiety. M, Met. X and Z, 
single-letter abbreviations for any amino acid residue. Yellow ovals denote the rest of a protein. 
D: Met-aminopeptidases cleave off the N-terminal Met residue if a residue at position 2 belongs to 
the set of residues shown101. Gly and Pro at position 2 are depicted in a different color because these 
residues, in contrast to other small residues, are rarely Nt-acetylated after the removal of N-terminal 
Met (Fig. 2B). 
 
Figure 2. The N-end rule pathway in Saccharomyces cerevisiae. A: The Arg/N-end rule 
pathway44. See the main text for details. Yellow ovals denote the rest of a protein substrate. 
‘Primary’, ‘secondary’ and ‘tertiary’ denote mechanistically distinct subsets of destabilizing 
N-terminal residues. The physically associated Ubr1 (N-recognin) and Ufd4 E3s have 
substrate-binding sites that recognize internal (non-N-terminal) degrons in substrates of the 
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Arg/N-end rule pathway that lack N-degrons. Ubr1 (but not Ufd4) recognizes N-degrons as well44. 
B: The Ac/N-end rule pathway3. Red arrow on the left indicates the removal of N-terminal Met by 
Met-aminopeptidases. This Met residue is retained if a residue at position 2 is nonpermissive 
(too large) for Met-aminopeptidases (Fig. 1D). If the (retained) N-terminal Met or N-terminal Ala, 
Val, Ser, Thr and Cys are followed by residues that allow Nt-acetylation (see the main text), these 
N-terminal residues are usually Nt-acetylated91-93. The resulting N-degrons are called AcN-degrons. 
The term ‘secondary’ refers to the necessity of modification (Nt-acetylation) of a destabilizing 
N-terminal residue before a protein can be recognized by a cognate Ub ligase. Proteins containing 
AcN-degrons are targeted for ubiquitylation and proteasome-mediated degradation by the Doa10 E3 
N-recognin, in conjunction with the Ubc6 and Ubc7 E2 enzymes44. Although Gly and Pro can be 
made N-terminal by MetAPs, and although Doa10 can recognize Nt-acetylated Gly and Pro, few 
proteins with N-terminal Gly or Pro are Nt-acetylated91-93. 
 
Figure 3. The mammalian Arg/N-end rule pathway. See the main text for details. N-terminal 
residues are indicated by single-letter abbreviations for amino acids. Yellow ovals denote the rest of a 
protein substrate. ‘Primary’, ‘secondary’ and ‘tertiary’ denote mechanistically distinct subsets of 
destabilizing N-terminal residues. C* denotes oxidized N-terminal Cys, either Cys-sulfinate or 
Cys-sulfonate, produced in vivo through reactions that require both nitric oxide (NO) and oxygen32,33. 
The mammalian N-recognins Ubr1, Ubr2, Ubr4 and Ubr5 (Edd) have multiple substrate binding sites 
that also recognize internal (non-N-terminal) degrons in other substrates of the Arg/N-end rule 
pathway, the ones that lack N-degrons. A question mark after Trip12 (which mediates the 
mammalian UFD pathway258 and is a sequelog of the S. cerevisiae Ufd4 E3) denotes the untested 
possibility that mammalian Ubr1 and/or Ubr2 form complexes with Trip12, by analogy with the 
Ubr1-Ufd4 complex in S. cerevisiae (Fig. 2A). 
 
Figure 4. Rule books of N-end rules. A: The N-end rule in eukaryotes. It results from 
combined activities of the Arg/N-end rule and Ac/N-end rule pathways3. In eukaryotes that produce 
NO, the N-terminal Cys residue (in yellow rectangles) can be targeted, alternatively, by either one of 
the two branches of the N-end rule pathway, with oxidized Cys marked by an asterisk (see Section 3). 
B: A comparison of rule books of N-end rule pathways in different organisms, indicated on the left. 
Black circles, blue or green triangles, and red crosses denote primary (Ndp), secondary (Nds) and 
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tertiary (Ndt) destabilizing N-terminal residues, respectively. Blue triangles denote secondary 
destabilizing N-terminal residues that involve either Nt-leucylation (in bacteria) or Nt-arginylation (in 
eukaryotes). Green triangles denote secondary destabilizing N-terminal residues that involve 
Nt-acetylation3. N-terminal Cys is denoted by both a green triangle and a red cross, given its 
alternative functioning as a part of NO/O2-mediated N-degrons or AcN-degrons. Open circles, in 
bacterial N-end rules, denote stabilizing (‘non-destabilizing’) N-terminal residues. Yellow circles, in 
eukaryotic N-end rules, denote Pro and Gly. These N-terminal residues are rarely Nt-acetylated and 
therefore, operationally, are usually stabilizing (‘non-destabilizing’) residues. But in some proteins 
with N-terminal Pro or Gly these residues can be Nt-acetylated. If other components of an 
AcN-degron are also in place (see Section 8), such proteins can become substrates of the Ac/N-end 
rule pathway3. 
 
Figure 5. Bacterial N-end rule pathways. A: The E. coli Leu/N-end rule pathway14,16,37. 
See Sections 3, 6 and 10 for details. The Aat L/F-transferase conjugates (largely) Leu to N-terminal 
Arg or Lys. N-end rule substrates bearing primary (bulky hydrophobic) destabilizing N-terminal 
residues are recognized by the ClpS N-recognin and are delivered for degradation to the ClpAP 
protease. B: The Leu/N-end rule pathway in another gram-negative bacterium, V. vulnificus, which 
contains both the Aat L/F-transferase and the Bpt L-transferase. As a result, N-terminal Asp and Glu, 
which are stabilizing (‘non-destabilizing’) residues in E. coli, are secondary destabilizing residues in 
the V. vulnificus Leu/N-end rule pathway37.  
 
Figure 6. Bpt L-transferases and ClpS N-recognins. A: Sequence alignments of bacterial Bpt 
L-transferases and eukaryotic Ate1 R-transferases37. The sequelogy (sequence similarity1) between 
Bpt and Ate1 encompasses more of their sequences than shown here37. Ate1 R-transferases lack a 
sequence motif (its consensus, in red, is shown at the top of the diagram) that Bpt L-transferases 
uniformly contain. This motif is characteristic of proteins that bind to a Fe-S cluster319,320 
(Section 10). B: Surface representation of the C-terminal domain of the E. coli ClpS N-recognin in a 
complex with an 11-mer peptide (shown as a stick model) that bears N-terminal Leu, a primary 
destabilizing (Ndp) residue in the Leu/N-end rule pathway74. Blue sphere, water molecule. C: Ribbon 
representation of the full-length 12-kDa ClpS in the same complex. D: Sequence alignments of the 
~70-residue domain of bacterial ClpS N-recognins in Caulobacter crescentus, E. coli, Deinococcus 
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radiodurans, Helicobacter pylori, Synechocystis sp. PCC6803 (the latter a photosynthesis-capable 
cyanobacterium), and in chloroplast (A. thaliana). This region of ClpS binds to N-terminal Ndp 
residues of the Leu/N-rule pathway. ClpS sequences are aligned with sequelogous regions of 
eukaryotic (S. cerevisiae, D. melanogaster, M. musculus, H. sapiens) Ubr1 N-recognins (they are 
~20-fold larger than ClpS) that encompass the type-2 substrate-binding site of Ubr1 (Fig. 7A). The 
specificity of this (type-2) Ubr1 binding site for bulky hydrophobic N-terminal Ndp residues is nearly 
the same as the specificity of ClpS, except that the Ubr1 site binds to N-terminal Ile as well (Fig. 2A), 
in contrast to ClpS (see the main text). Arrowheads indicate the positions of crystallographically 
determined contacts between the ClpS of C. crescentus and an N-end rule peptide73. Black cylinders 
indicate α-helices in this region of ClpS. 
 
Figure 7. Structural organization and phosphorylation of the Ubr1 N-recognin. 
A: Phosphorylated residues of the S. cerevisiae Ubr1 E3 N-recognin of the Arg/N-end rule pathway 
are indicated above the diagram39. The regions containing the type-1 substrate-binding site (UBR 
domain), the type-2 substrate-binding site, the BRR (basic residues-rich) domain, the Cys/His-rich 
RING domain and the AI (autoinhibitory) domain15,22,29,39,83-85 are also indicated. B: The ‘primed’ 
cascade of Ubr1 phosphorylation39. The initial phosphorylation of Ubr1 on Ser300 by the Yck1/Yck2 
kinases of the casein kinase type-I family makes possible (‘primes’) the subsequent, apparently 
sequential phosphorylation of Ubr1 by Mck1, a Gsk3-type kinase, on Ser296, Ser292, Thr288 and Tyr277. 
Also indicated is the identified function of the Ser300 phosphorylation of Ubr1 in the control of 
peptide import39.  
 
Figure 8. UBR domains in N-recognins and putative N-recognins of the mammalian 
Arg/N-end rule pathway. A: Ribbon diagram of the ~80-residue S. cerevisiae UBR domain83 
(Fig. 7A) in the complex with the RLGES peptide that bears N-terminal Arg, a type-1 Ndp residue28. 
The bound RLGES is shown as a stick model, with carbon atoms colored yellow. Several residues are 
marked with a black sphere and numbered to facilitate the tracing of the polypeptide chain. The 
names of residues of the RLGES peptide are in red, with the letter ‘s’ (‘substrate’) appended to their 
position numbers. Side chains of residues in the UBR domain that are present near missense 
mutations in UBR1 of patients with Johanson-Blizzard syndrome (JBS) (C.-S. Hwang, M. Zenker, 
H. K. Song and A.V., unpubl. data) are shown in a stick form, with carbon atoms colored green. 
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Three coordinated zinc ions of the UBR domain83 are shown as red spheres. B: Molecular surface of 
the S. cerevisiae UBR domain. Negatively and positively charged surfaces are shaded red and blue, 
respectively. The bound RLGES peptide is shown in yellow. Some residues of Ubr1 that comprise 
the N-degron-binding cleft are labeled83. C: Diagram of the mammalian UBR-domain family of E3 
Ub ligases, showing both UBR and other domains of these E3s (RING, HECT, PHD, CRD and 
F-box) that contribute to recognition and ubiquitylation of protein substrates31,43. Ubr1, Ubr2, Ubr4, 
and Ubr5/Edd of this set are operationally defined N-recognins of the mammalian Arg/N-end rule 
pathway in that they specifically bind to the type-1 and/or type-2 destabilizing N-terminal residues, 
whereas Ubr3, Ubr6, and Ubr7 are not N-recognins43,274 (Section 9.1). 
 
Figure 9. Splicing-derived isoforms of the Ate1-encoded Arg-tRNA-protein transferase 
(R-transferase) and its inhibition by hemin. A: The bidirectional DfaPAte1 promoter (containing a CpG 
island) upstream of exon 1B of the mouse Ate1 gene35,282. Green arrows indicate transcriptional units 
oriented in both directions from DfaPAte1, and also from an unmapped ‘upstream’ promoter that 
mediates the expression of Ate1 transcripts containing exon 1A. The locations and sizes of some Ate1 
exons are shown as well. B: The exons, including alternative exons, of the mouse Ate1 gene, with 
deduced lengths of the corresponding polypeptide segments indicated on top. C: Mouse R-transferase 
isoforms (and their designations) that are produced through alternative splicing of Ate1 pre-mRNA. 
D: Sequence comparisons of translated vertebrate Ate1 exons 1A amongst themselves and with the 
set of longer but also sequelogous alternative exons 1B. Most of recurrent amino acid identities are 
highlighted by color. Mus musc., mouse;  Rattus norv., rat; Homo sap., human; Gallus gall., chicken. 
E: The mouse ATE11B7A isoform, with locations of significant Cys-containing motifs, including the 
vicinal Cys71 and Cys72 residues. A disulfide bond between them is the result of hemin-mediated 
oxidation and functional inactivation of R-transferase35. F: Diagram of the previously proposed35 
redox mechanism of the hemin-mediated disulfide formation between Cys71 and Cys72 of Ate1. 
 
Figure 10. Confirmed and putative N-end rule substrates produced by caspases and other 
nonprocessive proteases. Amino acid residues are indicated by single-letter abbreviations. 
Arrowheads and enlarged residues, in red, indicate the cleavage sites and N-terminal residues of the 
corresponding C-terminal fragments. A number on the left represents the first residue of a protein 
(numbered as in the full-length protein) that is shown in the diagram. A number on the right 
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represents the last residue of a full-length protein. The prefixes Dm, Hs, Mm, and Sc refer to proteins 
of D. melanogaster, H. sapiens, M. musculus and S. cerevisiae, respectively. See Section 5 for a 
description of specific protein fragments cited in this list. 
 
Figure 11. Organization and cis-trans targeting of eukaryotic N-degrons. A: Three 
determinants of N-degron. d, a destabilizing N-terminal residue. K, a ‘ubiquitylatable’ internal Lys 
residue. The absence of one of these determinants abrogates polyubiquitylation of a protein, despite 
the presence of another determinant. The third determinant of N-degron is an unstructured region that 
is required for polyubiquitylation and/or the initiation of degradation of a polyubiquitylated N-end 
rule substrate by the 26S proteasome. See Section 5 for references and details. B and C: cis versus 
trans polyubiquitylation of an oligomeric N-end rule substrate that results in the degradation of a 
subunit that becomes linked to a poly-Ub chain13 (see Section 5). D: trans-degradation, in which a 
specific subunit of oligomeric protein is polyubiquitylated but is not degraded by the 26 proteasome, 
for example, because it lacks an unstructured region that is required for the initiation of degradation. 
Instead, a subunit-selective degradation of another, non-ubiquitylated subunit takes place. This mode 
of degradation was demonstrated by the Matouschek laboratory 168 for oligomeric substrates of the 
UFD pathway. It remains to be determined whether the analogous (hypothetical) trans-degradation of 
an oligomeric N-end rule substrate can also occur. E: The 1989-1996 hairpin insertion model of 
protein targeting by the 26S proteasome5. No details of the 26S proteasome structure (such as the 
19S regulatory particle (RP)) are shown in this 1996 diagram5, and the sizes of specific components 
such as Ub moieties, the poly-Ub chain and the proteasome, are not to scale (see Section 5). 
 
Figure 12. Targeting and degradation of N-end rule substrates by the bacterial Leu/N-end rule 
pathway. This model, proposed by Román-Hernandez et al.82 and based on studies by the Baker, 
Sauer, Bukau, Maurizi and other laboratories16,75,76,78,81,82, is described in the main text. A folded 
polypeptide chain of an N-end rule substrate (in purple color) is depicted ‘explicitly’, in contrast to 
solid-body renderings of ClpS and ClpAP. Black circles in the ClpP moiety indicate its proteolytic 
active sites. See Section 5 for details. 
 
Figure 13. Steric shielding of the Nt-acetylated N-terminal residue of a subunit in a protein 
complex. Shown here is a part of the crystal structure, by the Barford laboratory, of a complex 
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between the Hcn1 and Cut9 subunits of the S. pombe APC/C Ub ligase247. In this structure, the 
Nt-acetylated N-terminal Met residue of Hcn1 is enclosed within a chamber formed by the Cut9 
subunit, including its interface with the other Cut9 subunit in the heterotetramer of Hcn1 and Cut9. 
N-terminal region of Hcn1 is shown in cyan as a stick model, and Cut9 is depicted as a cut-out 
surface representation, to show the chamber’s interior247.  
 
Figure 14. Spalogy (spatial similarity1) between the Ntaq1 NtQ-amidase and Factor XIII 
transglutaminase. A and B: Crystal structures of the human Ntaq1 (C8orf32) NtQ-amidase340 
(PDB 3C9Q) and FXIII transglutaminase341 (PDB 1FIE),  respectively. C8orf32 is an initially 
uncharacterized human protein the structure of which was deposited in the Protein Data Bank 
(PDB 3C9Q) by the Center for Eukaryotic Structural Genomics340, and was later shown, by Wang et 
al.42, to be the Ntaq1 NtQ-amidase. C and D: Structures around the active sites of Ntaq1 NtQ-amidase 
and Factor XIII transglutaminase, respectively. These regions are circled in A and B. C and D: The 
catalytic triad (Cys314, His373, and Asp396) of Factor XIII transglutaminase (D) (ref. 341) and the 
corresponding residues (Cys28, His81, and Asp97) of human Ntaq1 (C) are indicated. Despite the 
striking spalogy between these regions of two enzymes (C and D), there is no significant sequelogy 
(sequence similarity) between them42. 
 
Figure 15. Regulation of peptide import by the Arg/N-end rule pathway in S. cerevisiae, and inputs 
by the amino acid-sensing SPS pathway. A: The ‘primed’ cascade of Ubr1 phosphorylation in which the 
Yck1/Yck2-mediated phosphorylation on Ser300 of Ubr1 is essential for the normal regulation of 
peptide import39 (see also the legend to Fig. 7A, B). B: Ubr1-mediated regulation of peptide import, 
and the involvement of the SPS pathway27,29,138,295,296. Cup9 is a transcriptional repressor of the 
regulon that includes PTR2, which encodes the major importer of di/tripeptides. In the absence of 
Ubr1 (in ubr1∆ cells), Cup9 becomes long-lived, accumulates to high levels, and extinguishes 
expression of Ptr2. Therefore ubr1∆ cells cannot import di/tripeptides. In wild-type (UBR1) cells 
growing in the absence of extracellular di/tripeptides, a relatively low but non-zero number of Ubr1 
molecules have their third substrate-binding site ‘open’ (not autoinhibited) and therefore can target 
Cup9 for degradation (t1/2 ~ 5 min) via its internal degron, resulting in a low but significant 
steady-state concentration of Cup9 and thus a weak but significant expression of the Ptr2 transporter. 
In wild-type (UBR1) cells growing in the presence of extracellular di/tripeptides (some of which bear 
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type-1 and type-2 destabilizing N-terminal residues), the imported peptides interact with the type-1 
and type-2 binding sites of Ubr1. This binding allosterically increases the fraction of Ubr1 molecules 
whose third (Cup9-specific) site is ‘open’ (active). The resulting decrease in the half-life of Cup9 
(from ~5 min to below 1 min) results in a low concentration of Cup9, and consequently to a strong 
induction of the Ptr2 transporter27,29,138. Also shown is the amino acid-sensing SPS pathway (see 
Section 9.4 for details and additional references), which can influence the import of peptides at least 
in part through the Yck1/Yck2-mediated phosphorylation of Ubr1 on Ser300. This phosphorylation is 
required (through a mechanism that remains to be determined) for normal levels of Ubr1 activity in 
the Ptr2-Cup9-Ubr1 circuit39. 
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